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ABSTRACT 
Cholera toxin (CT) produced by Vibrio cholerae is the causative agent for the 
diarrheal disease cholera. Cholera is yearly afflicting millions and is estimated 
to kill over 100 000 people every year. In this thesis I aimed to better 
understand the role of noncanonical CT receptors, e.g. receptors other than 
the glycolipid GM1. Epidemiological studies have found a link between cholera 
severity and blood group indicating that histo-blood group antigens (HBGAs) 
could play a role as receptors for CT. The work presented in this thesis shows 
that CT readily binds to the HBGA Lewis X on cells and on some cells CTB 
binding correlates with the level of Lewis X. Furthermore, we show that other 
fucosylated glycans such as Lewis Y, A/BLewis Y and 2´-fucosyllactose (found 
in human breast milk) readily inhibit CT binding to cell lines and primary cells 
from human small intestine. In contrast, sialylated or non-fucosylated glycans 
did not show any inhibitory effect on CT binding to human cell lines indicating 
a fucose-dependent binding. This was further confirmed in blocking studies 
using long synthetic polymers displaying glucose, fucose, galactose or a mix of 
the latter two. Functional evaluation identified that the fucose-binding lectin 
AAL completely blocked the effect of CT, but so could the galactose-binding 
lectin PNA. The galactose-fucose polymers yielded a partial inhibition of CT 
intoxication of human small intestinal enteroids whereas GM1 glycan 
completely blocked the effect of CT. Hence, fucosylated glycans are involved 
in attachment of CT to the intestinal wall. However, if this binding assists or 
counteracts subsequent internalization by other receptors carrying terminal 
galactoses remains to be determined. Importantly, these receptors can be 
other glycans than GM1 as this thesis show GM1-independent CT-mediated 
intoxication. 
Keywords: Cholera toxin, Lewis antigen, HBGA, HMO, fucose, GM1 
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SAMMANFATTNING PÅ SVENSKA 
Kolera är en allvarlig diarrésjukdom som kan ha en dödlighet på över 50 % 
om de drabbade inte får sjukhusvård. Standardbehandlingen för kolera är 
oral vätskeersättning och vid svårare fall även intravenös vätska och 
antibiotika. Numera finns även vaccin mot kolera som har god effektivitet, 
men långt ifrån alla som har risk att drabbas av kolera är vaccinerade. Kolera 
drabbar främst människor i Gangesdeltat och länder i Afrika söder om 
Sahara.  
Kolera orsakas av koleratoxin som utsöndras av bakterien Vibrio cholerae. 
Koleratoxin produceras först när bakterien har nått tunntarmen och där 
binder det till det yttersta cellagret. Under 1970-talet upptäcktes att en 
glykolipid (socker kopplat till en fettkedja) på cellens yta kallad GM1 kunde 
binda koleratoxin. GM1 kunde på så vis möjliggöra upptag av toxinet in i 
cellen.  Väl inne i cellen så tar koleratoxin över delar av cellens signalsystem. 
Detta leder i sin tur till att stora mängder salter och vatten utsöndras i 
tunntarmen. Effekten av detta blir en mycket kraftig diarré som kan ge 
vätskeförluster på så mycket som en liter i timmen.  
Majoriteten av de studier som är gjorda beträffande hur koleratoxin förgiftar 
celler med hjälp av GM1 är gjorda med cellinjer och djurförsök. Tyvärr kan 
dessa metoder inte fullt ut representera hur koleratoxin påverkar den 
mänskliga tunntarmen. Tidigare har det också visats att koleratoxin förutom 
GM1 också binder andra sockermolekyler. Denna typ av receptorer har inte 
utforskats i lika hög grad som GM1. Vi ville därför undersöka vilken roll den 
nya typen av receptorer har för koleratoxin. Dessa experiment utfördes 
därför med vävnad från mänsklig tunntarm. Vi använde oss även av möss 
som saknar förmågan att framställa glykolipiden GM1 i våra studier. Dessa 
möss liknar människor då vi har mycket låga nivåer av GM1 i våra tarmar.  
I denna avhandling kan vi visa att sockermolekyler som är eller liknar 
blodgruppsmolekylerna i ABO-systemet har stor inverkan på koleratoxin-
bindning till celler från mänsklig tunntarm. Detta medför att den stora 
majoriteten koleratoxin inte binder till GM1 som man tidigare trott.  
Vi visar också att andra receptorer än GM1 påverkar diarrén i både mus och 
människa. Bindningen av koleratoxin till dessa receptorer är till mestadels 
beroende på sockret fukos men även sockret galaktos är viktigt.  
Slutligen kan vi påvisa att bindningen av koleratoxin till celler från mänsklig 
tunntarm, kan blockeras av långa syntetiska kedjor med fukos och galaktos.  
Vi ser även indikationer på att dessa kedjor kan blockera effekten av 
koleratoxin. Detta gör att de är potentiella kandidater för att förbättra 
behandlingen med vätskeersättning vid kolera. 
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INTRODUCTION 
CHOLERA  
The diarrheal disease cholera is a well-known old plague of the human 
population and is caused by the Gram-negative bacteria Vibrio cholerae (V. 
cholerae). The extreme diarrheal fluid loss associated with cholera disease can 
kill a healthy adult human quickly if not treated. Annually it is estimated that 
3 million people are affected by cholera, with about 100 000 deaths 
worldwide as a result. It's hard to get exact data on number of cases due to 
poor surveillance and a lot of cases occurring in areas with limited 
infrastructure or in areas of armed conflict (1,2).  
The work presented in this thesis aim at a better understanding of the main 
cause behind cholera; cholera toxin. More specifically I was interested in how 
noncanonical receptors interact with cholera toxin (CT). The canonical 
receptor for CT has been known for about 50 years and is a glycolipid called 
GM1 with very high affinity for CT. Despite being able to facilitate CT 
intoxication GM1 is not the sole binder of CT on the cellular surface. For this 
reason, I was interested in further investigating these novel types of receptors 
and aimed to evaluate their functional role. I also identified a lack of data 
regarding CT binding to primary infected tissue in the human small intestine. 
Using this new knowledge, I was interested in evaluating different blocking 
agents to prevent CT intoxication.  
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CHOLERA EPIDEMIOLOGY 
Cholera primarily affects poor regions where there is limited access to clean 
drinking water and good sanitation. Africa is the most affected continent with 
60% of recorded cases and almost 70% of deaths, but south Asia (primarily 
Ganges delta) and the Middle East as well as Haiti have endemic cholera (2). 
Outbreaks often occur during flooding when the drinking water supplies are 
contaminated with fecal matter or bacterium from otherwise isolated water 
containing V. cholerae. In fact, V. cholerae is normally resides in fresh and saline 
water all year round, mainly causing disease during the rainy season. This 
means that even endemic areas have a large variance over the year in the 
number of cholera cases similar to non-endemic outbreaks (3,4).  
It is believed that cholera was originally only endemic in the Indian 
subcontinent (primarily the Ganges delta), but with the development of fast 
and frequent travel cholera has been able to spread and cause epidemics and 
also pandemics elsewhere. In fact, since 1816 there have been seven 
documented cholera pandemics responsible for the deaths of tens of millions 
of people. The first recorded pandemic (1816–1826) began in the Ganges 
delta and spread across India, China, Indonesia and as far west as the Caspian 
Sea. The following five pandemics of cholera (between 1829-1923) also had 
recorded large outbreaks in Europe and in the Americas (5-7). These six 
pandemics were caused by V. cholerae O1 of the “classical” biotype, whereas 
the seventh pandemic was started in the 1960s and which is currently ongoing, 
is caused by the other biotype “El Tor”. This seventh pandemic which started 
in Indonesia and not India as the previous ones had, is the most extensive in 
regards to its duration and its geographical spread (8,9). A more detailed 
overview of the different V. cholerae strains can be found below. 
The cause of the longevity of the current seventh pandemic can be explained 
by the modern changes in the speed and frequency of travel. The El Tor 
biotype has taken over as the primary cholera-causing organism from the 
classical biotype (7,9). It has been suggested that the El Tor biotype is better 
suited for surviving in the environment and hence will be more likely to infect 
humans than the classical biotype (10). This appears a more plausible 
explanation than differences in pathogenic capacity since infection with either 
El Tor or classical biotype O1 V. cholerae can be equally severe and 
immunological protection against reinfection are comparable (7,9,11).  
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The most common infection route is via contaminated water or food since a 
relative high number of bacteria (103-108) need to enter the stomach to 
successfully colonize the small intestine. The bacteria are sensitive to the 
acidic environment of the stomach so individuals with high stomach pH are 
far more susceptible, to infection (12,13). The infection is often cleared within 
a week by the host’s own immune system and antibiotics are seldom needed 
as a part of the hospital treatment (1). 
Another important risk factor for cholera is being a child under 5 years old. 
Also, previously unexposed adults run a great risk of contracting cholera 
during an outbreak (14). This is most likely due to the lack of preexisting 
immunity (as in young children) that adults living in endemic areas often have 
due to repeated exposures to V. cholerae (1,4,14). There have been some 
reports on cholera being more prevalent in HIV-infected individuals during 
outbreaks, but bigger studies have to be conducted to verify this link (15). 
However, this would be in line with the hypothesis that preexisting immunity 
to V. cholerae is a large contributing factor to why cholera outbreaks is not 
affecting even more people in endemic areas. An elevated risk of sever cholera 
can be seen in blood group O-positive individuals. The risk for infection is 
however not altered indicating that the blood group antigen could be involved 
in the cellular uptake of CT (16,17).  
 
VIBRIO CHOLERAE 
Like for all bacterial species V. cholerae is a name that groups several 
genetically similar, yet distinct sub strains together. In order to understand 
the world around us we humans have a strong need to classify things into 
categories. This need for classification is very useful in studying all forms of 
life but in the case of bacteria it also becomes a huge and difficult task. Since 
bacteria have such a high reproduction rate the phenotypic and genetic 
variation is often large. To handle such large diversity there are several 
classification systems that work together to generate a more comprehensive 
picture of reality. In the case of V. cholerae it can be divided into serotypes on 
the basis of how they are aggregated by serum antibodies. This classification 
only considers the differences that strains have on the surface but is a good 
indicator that there is a significant genetic variation between strains. 
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Serotypes can be grouped into serogroups where only smaller differences can 
be detected. One can also take a genetic approach and classify genetically 
identical/very similar strains into biotypes. Since the difference between 
biotypes can sometimes only be noticeable on the inside of the cell, the same 
serogroup or serotype can have different biotypes. Ergo, biotype is the level 
of classification that has the most resolution but is also requires the most 
work to determine.  
V. cholerae is usually an environmental-residing Gram-negative bacteria, and 
although cholera is a human exclusive disease, humans are not the only natural 
host. Several aquatic animals and alga are carrying the bacteria as a symbiont 
or as part of the commensal flora (18). In fact, out of the 200 serogroups that 
exists, only the O1 and O139 cause major outbreaks of cholera disease. The 
current pandemic is predominantly caused by serogroup O1 of the El Tor 
biotype (19). The serogroups O1 and O139 carry the bacteriophage (CTXF) 
coding for CT as well as other virulence factors. The vast majority of the over 
200 V. cholerae serogroups do not cause cholera but might cause other 
diseases in humans. In fact, the vast majority of V. cholerae strains isolated 
from the environment around human settlements are not carrying all the 
virulence factors necessary to cause cholera (2,20-22). 
CTXF is a filamentous bacteriophage that contains genes coding for CT and 
two other toxins as well as structural virion proteins (23,24). The two other 
toxins are accessory cholera enterotoxin (Ace) and zonula occludens toxin 
(Zot). Ace and Zot seem to be able to contribute to the diarrhea in cholera 
as shown in animal models and human cell lines (25,26). However, the vast 
majority of the diarrhea in cholera is caused by CT (23). The phage originally 
differed between the two major biotypes of cholera-causing bacteria. In the 
beginning of the seventh pandemic the emerging El Tor biotype had its own 
variant of CT where the B-subunit differs at amino acids 18 and 47. However, 
over time the classical CT-genes took over and now the El Tor biotype 
bacteria express the classical CT (27,28). This fact can lead to some confusion 
in the field about what type of CT to use in studies.  We consistently used 
the classical CT in this thesis as we consider this one to be the most clinically 
relevant. 
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The Vibrio cholerae pathogenicity island (VPI) element carries genes necessary 
for the formation of the toxin-coregulated pilus (TCP), a type IV pilus that is 
thought to mediate adherence and colony formation during intestinal 
colonization of neonate mice and humans (29,30). The VPI element also 
carries genes that encode two transcriptional activators, Tox T and TcpP, 
which regulate the production of both TCP and CT. In addition, V. cholerae 
O1 and O139 have several other genetically encoded virulence factors, which 
enable the bacteria to effectively colonize and cause cholera disease in the 
small intestine. This includes a flagellum enabling the bacteria to swim and 
thus withstand the constant outward motion of the mucus layer fluid. It is also 
important that V. cholerae can penetrate the small intestinal mucus layer (31). 
This is accomplished with the aid of a mucus degrading protease (mucinase) 
(31,32). The ability to traverse the intestinal mucus layer is of a high 
importance to the bacterium, since closer proximity to the epithelium likely 
ensures better intestinal colonization (31). By entering the mucus layer V. 
cholerae also escapes the high concentrations of bile in the upper small 
intestine. Bile is bactericidal to V. cholerae and can also be sensed as a 
chemorepellent by the bacteria (31).  
CT induced fluid secretion also correlates with rapid depletion of mucus 
production. This indicates that the mucus producing goblet cells are sensing 
and responding to the toxin onslaught but fail to eliminate the bacterial 
infection (33-35). The mucus release form goblet cells is also regulated by the 
same signal molecule that CT induces an overproduction of; cAMP. It is 
therefore possible that CT intoxicated goblet cells quickly release all stored 
mucus, but this needs to be proven experimentally (34,36). 
The rather big family of V. cholerae strains can be divided into several 
subgroups with regards to reactivity to serum antibodies. First the strains are 
divided into serogroups where bacterial strains with similar reactivity cluster 
together. There are over 200 serogroups that can be further subdivided into 
serotypes Inaba or Ogawa. The only difference between Ogawa and Inaba 
serotypes is that Ogawa has a terminal methylation on its lipopolysaccharide 
(LPS) that Inaba lacks due to an inactive methyltransferase. This small change 
in the LPS synthesis has a great impact of bacterial fitness and ability to cause 
cholera. As to why the Ogawa strains of serogroup O1 have outcompeted 
the Inaba strains is still not fully understood (37,38). 
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CHOLERA TOXIN 
CT is a holotoxin with a binding (CTB) and a catalytically active part (CTA). 
CT is made up of one CTA subunit and five identical B-subunits that are 
organized in a pentamer ring with a hollow middle as seen on the cover of 
this thesis. The pentamer structure is sensitive to heat and pH and must be 
intact to enable binding of the main ligand GM1 (39). GM1 is a glycolipid and 
will be discussed in more detail in a later section. CTA is positioned in the 
hollow center of the CTB pentamer and can be further subdivided into CTA1 
and CTA2. CTA2 is responsible for attaching CTA to the CTB pentamer. 
Upon internalization CTA1 is cleaved from CTA2 and is free to migrate inside 
the cell. CT intoxication will be covered in more detail later in this text 
(40,41).  
CT gene expression is under complex regulation under the ToxR regulon 
cascade, and is turned on by sensors recognizing intra intestinal components 
such as bile (42-44). CTA and CTB are coded and translated separately and 
then assembled in the periplasmic space of V. cholerae. The level of translation 
does not seem to differ dramatically between the two subunits and therefore 
a surplus of CTA will build up that has to be handled by the bacteria (45). The 
fully assembled toxin is then secreted from the bacteria via a type II secretion 
system into the environment or, during infection, into the intestinal lumen 
(46,47). 
In the early seventies the glycolipid GM1 was discovered to bind strongly to 
CT and proven to act as a receptor for uptake (48-50). The affinity between 
CTB and GM1 is very high for a protein glycan interaction. This high affinity 
stems from the branched nature of GM1. The GM1 glycan consists of a stem 
glycan with glucose, galactose and GalNAc terminating in a galactose. 
Attached to the core galactose is a sialic acid which provides two distinct 
“handles” for a protein to grab on to (51). Each subunit of CTB can bind the 
terminal galactose of GM1 via a deep pocket located on the basal side (when 
viewing CTA as protruding from the top of CTB) in the middle of the subunit 
(Fig 1) (40). The sialic acid pocket is a bit shallower and located in the junction 
between two CTB subunits. This double pocket binding of GM1 is the reason 
for the high affinity and is highly dependent on the pentameric organization of 
the CTB subunits (Fig 1). The bond is sometimes referred to as a two-finger 
grip with galactose as the index finger and sialic acid as the thumb (49,52,53). 
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Figure 1. CTB in complex with GM1. A computer rendering of the surface of CTB 
obtained from X-ray crystallography with two GM1 glycans bound (PDB-ID: 2CHB). All the 
subunits for CTB are not fully shown but all have a distinct color to better visualize the 
transition between each. The individual sugars are color coded to visualize the galactose 
(yellow) and sialic acid (purple) binding pockets. The blue glucose residue is normally attached 
to ceramide in the cell membrane. 
Most of the binding strength is dependent on galactose although sialic acid 
also plays an important role in stabilizing the binding. This site primarily binds 
to GM1 but also binds to other oligosaccharides with terminal galactoses such 
as asialo-GM1 with low affinity (54). GM1 has since long been confirmed as a 
functional receptor for CT intoxication in rabbit intestine and human cell lines 
(49,55-57). CT binding has been shown to correlate with the varying levels of 
GM1 in intestines of some species, but not for all cell types or tissues. It is 
therefore clear that other binders exists on cells of various tissues (49,58-
60).  
Interestingly, a noncanonical site has also been discovered but has been less 
well characterized for both receptor specificity and functional significance (61-
63). It accepts several types of fucosylated oligosaccharides such as the histo-
Galactose
GlcNAc
Glucose
Sialic acid
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blood group antigens (HBGAs) A and O as well as Lewis Y and X albeit at 
much lower affinities than for GM1 (61-64). Much of the work in this thesis 
has been focusing on understanding this new site and what role it plays in CT 
intoxication. 
 
EXTRACELLULAR BINDING 
As mentioned above CT is produced by V. cholerae, assembled in the bacterial 
periplasm and then secreted into the surroundings via type II secretion system 
(65,66). The bacterial production of CT is initiated upon small intestinal 
infection. CT binding to epithelial cells is greatly increased by several virulence 
factors such as the flagella and a mucinase. These virulence factors together 
enable toxin secretion in closer proximity to the apical side of the epithelial 
cells.  
For about 50 years the ganglioside GM1 has been considered the only 
receptor for CT uptake. The glycolipid GM1 consists of a constant glycan and 
a lipid tail that can vary in composition (67). The affinity of the CT-GM1 two-
finger grip is storing and has a Kd in the mid pM to low nM range, varying 
somewhat depending on the assay used (54,68-71). A schematic drawing of 
how CT enters and intoxicates cells can be seen in figure 2. It has also been 
shown that the level of GM1 on a cell type correlates with CTB binding and 
that incorporating exogenous GM1 into cell membranes both increases CT 
binding and the intoxication level of the cells (49). Additionally, numerous 
groups have shown that GM1-os or GM1-like molecules readily block CT 
intoxication in both animals and human cell lines. Together this proves beyond 
a doubt that GM1 can act as a cellular receptor (72-74). However, not all cell 
types show a correlation between binding of CTB and the level of GM1. This 
indicates that there are one or several other receptors for CT and that the 
receptor repertoire may vary between different species and tissues (58-60). 
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Figure 2. Classical view on intoxication pathway for CT. A schematic drawing of how 
todays consensus regarding CT intoxication of epithelial cells in the human small intestine. 
 
INTERNALIZATION 
Over the years there has been some controversies regarding CT uptake. One 
such argument is if CT uptake is clathrin-dependent or mediated by calveolar 
uptake in lipid rafts (75-78). However, the most reasonable standpoint when 
summarizing the findings is that CT can enter cells via various pathways and 
uptake systems. The uptake route clearly varies between different cell types 
but also within cells, again indicating that there are several types of receptors 
for CT (75,79). It is important to note, that only a minority of the CT that is 
taken up can effectively contribute to intoxication, which again is indicative of 
several uptake routes and/or several receptors also within the same cell (80). 
To my knowledge no one has thoroughly mapped CT uptake in primary cells 
from human small intestine. This would of course be of high interest since 
these are the cells that during natural infection are exposed to CT. 
Upon internalization CT begins a complicated journey from the cell 
membrane via the Golgi and ER to eventually assert its effect in the cytosol 
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(Fig 2). First CT is retrogradely transported from the surface in endosomes 
to the trans-Golgi network. From there CT is further transported to the ER 
and from that point able to traffic back and forth between the ER and Golgi, 
awaiting recognition by chaperones. Although the CTA-chain is cleaved into 
CTA1 and CTA2 well before entering the ER by serine protease cleavage and 
disulfide-bond reduction they still stick firmly together (81). It is only with the 
help of protein disulfide isomerase that CTA1 can escape the rest of the toxin 
complex (82,83). In light of recent findings the exact role that the protein 
disulfide isomerase plays in the detachment of CTA1 is less clear and other 
proteins such as Hsp70, Hrd1 and BiP are also involved in the dissociation 
(84,85). Once free CTA1 is recognized as a miss-folded protein, it is 
transported into the cytosol for degradation. Upon entering the cytosol 
CTA1 escapes degradation and facilitates ADP-ribosylation of Gs-alpha with 
the help of ADP-ribosylation factor 6 (Fig 2) (80,85). 
 
TOXICITY 
The toxic effect of CT begins with CTA1 facilitating activation of ADP-
ribosylation of Gs-alpha (Fig 2). Activated Gs-alpha will in turn activate 
adenylate cyclase which converts adenosine triphosphate to cyclic adenosine 
monophosphate (cAMP) (86,87). Consequently, high levels of cAMP then 
activates protein kinase A, which phosphorylates and activates the protein 
cystic fibrosis transmembrane conductance regulator (CFTR) (Fig 2) (88). In 
turn, activated protein kinase A also triggers trafficking of CFTR from 
endosomal storage to the host cells surface, further increasing the ion 
secretion. CFTR specifically transports intracellular chloride ions into the 
intestinal lumen generating a huge osmotic imbalance (89). Trying to return 
to homeostasis the cells secrete other ions and water into the intestinal 
lumen. With this the full intoxication pathway of CT is completed (Fig 2).  
In fact, CT is not necessarily toxic to the cells it enters and the intestinal 
barrier function is not greatly affected in mice when challenged with a 
moderate dose of CT (90). Some have reported aberrant translocation of 
molecules important for tight junctions in the small intestine with high doses 
of CT in mice and drosophila. Others have shown that barrier disruption can 
occur upon V. cholerae infection and high-dose CT challenge, but that this 
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phenomenon is strain specific (91,92). In human cell lines it has been shown 
that CT disrupts the formation of protein complexes important for the 
formation of tight junctions (93). The vast majority of the fluid comes from 
the intestinal blood vessels and can even be inhibited via interference with 
nerves responsible for vasodilatation and is actively secreted by enterocytes 
(94-96). 
Given the general nature of intracellular cAMP-sensing and protein kinase A 
activity, several other cellular processes are also affected by CT intoxication 
(97-99). Those CT-induced effects include immunostimulatory effects as well 
as redistribution of intercellular adhesion molecules and metabolic changes. 
In fact, several attempts are currently ongoing to utilize mutated or modified 
versions of CT as adjuvants in oral vaccines. Oral vaccines are rare today but 
could prove beneficial since the immunity would be localized to the gastro-
intestinal and airway tracts where most of the infections occur. In order to 
break tolerance and induce an immune response in the gut, a potent adjuvant 
is needed compared to intradermal injections that are common today (100-
104). 
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IMMUNITY AND CHOLERA 
Cholera is fairly limited in the endemic areas compared to outbreaks in naïve 
populations. This can largely be attributed to development of immunity against 
V. cholerae and CT (1). This is also the reason that young children without a 
preexisting immune response are at much higher risk for developing cholera. 
To better understand the role of the immune system in regulating V. cholerae 
infection, we first need to go through the basics of immunology.  
To deal with the constant onslaught from the microorganism, we need a 
complicated immune system devoting special cells for the task of defending 
the acquired recourses. Immunity can be divided into two parallel but 
connected subsystems called innate and adaptive immunity. The innate system 
has a set and limited number of receptors for recognition of microbes and 
stress signals from dying cells but does not have a long-term memory function. 
Innate immunity is built up of cells and secreted molecules. It has a fast 
response time and can eliminate microbes. This function can be enhanced by 
the help of cells of adaptive immune system (105-107). Innate immune cells 
also get rid of dying cells in the absence of a local inflammation that damages 
the surrounding tissue. Local inflammation is otherwise the cardinal sign of 
the immune system combating infectious organisms.    
The cells of the adaptive system on the other hand only recognize one small 
part of a pathogen or foreign biomolecule called antigens. This means that the 
individual cells are highly specific and thereby effective at finding and 
eliminating the target. It also means that they are practically useless against all 
other pathogens. The large amount of energy spent on developing this 
adaptive cellular repose would be a waste if there was no memory function 
built into the system saving the effective cells for future reinfections (108). To 
generate an antigen specific cell takes a long time compared to cells of the 
innate immune system, but once generated they are long lived and can persist 
in the body for decades. This is the reason that vaccines can be effective for 
so long. Although the innate system is the older of the two, adaptive immunity 
can be found at least as far back on the evolutionary time scale as the 
emergence of vertebrates (109).  
The two main types of cells in the adaptive immune system are B and T cells. 
The cell types directly translate to the concepts of humoral and cellular 
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immunity (110). B cells representing humoral immunity largely depend on the 
secretion of glycoproteins called antibodies as a defensive mechanism against 
invading pathogens and toxins (111). Upon activation, B cells produce and 
secrete large quantities of antibodies of various types, discussed further in a 
section below. Antibodies are designed for binding to specific targets and can 
thereby be used to mark pathogens for destruction or prevent pathogen or 
toxin binding to cells (111-113).  
T cells on the other hand need to be in direct contact with other cells to elicit 
their effect. Instead of antibodies, T cells utilize the T cell receptor (TCR) to 
interact with an antigen presenting molecule present on all cells, the major 
histocompatibility complex (MHC) (114,115). TCR interaction with MHC 
enables specific presentation of intracellular antigens present inside the cells 
and act as a health check for cells. Infected or tumor cells will have an altered 
protein transcription profile and thereby present a different set of antigens 
on the MHC. Effector T cells then eliminate cells that are recognized as 
infected or tumor cells but lack the capacity to combat extracellular bacteria 
like V. cholerae (116).  
Both B and T cells have the unique ability to recombine the DNA coding for 
antibodies and TCR respectively. This fact enables the creation of receptors 
that can recognize pathogens never before encountered (117). The 
recombination of these receptor gene segments (called V, D and J-segments) 
is a stochastic process in both B and T cells, resulting in an extreme diversity 
in receptors(118). Most of those clones are deemed  unsuitable and deleted 
soon after the recombination event. However, a few are selected for after a 
rigorous process to avoid reactivity to own tissues (119). The now genetically 
unique B and T cells start to patrol the blood stream and various lymph nodes. 
In this state they are naïve an unable to respond effectively even if they 
encounter the antigens they are set to detect. To become activated and 
thereby fully functional they need professional antigen presentation in a lymph 
node (120-122). 
Adaptive immunity depends on the innate system for selecting the right cells 
that recognize a certain pathogen. This crosstalk between the systems is 
mainly mediated via dendritic cells. Dendritic cells patrol tissues and upon 
encountering a suspicious material will transport this to the lymph nodes 
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(122). In the lymph nodes dendritic cells interact with a special type of T cells 
called T-helper cells and activates them. Activated T-helper cells can in turn 
interact with B cells presenting that antigen on MHC. The antigen has been 
internalized using its surface-bound antibody and is therefore a good 
representation of the antibody’s ligand. T-helper cells can then selectively 
activate the right kind of B cells to combat the pathogen (119). Upon 
activation B-cells will undergo Ig class switch and start producing antibodies 
if IgG-, IgM-, IgA- or IgE-type (123).  
For combating extracellular bacteria in the intestine like V. cholerae the most 
important type is IgA since it is actively secreted over mucosal surfaces (124). 
IgA therefore has the ability to neutralize pathogens and toxins before they 
reach the epithelial cells and thereby conferring complete immunity to the 
effects of a V. cholerae exposure (14). It has been shown that a significant 
portion of antibodies produced during a natural infection with V. cholerae are 
directed against CT (125,126). IgA antibodies against CT in breast milk also 
correlates with protection from cholera underlining the importance of 
antibodies, but possibly also other components in breast milk (127-129). 
Another common antigen for antibodies is the cell wall component LPS 
(125,126). LPS is sensed by the toll-like receptor 4 present on cells of the 
innate immune system resulting in direct activation and secretion of pro-
inflammatory cytokines (130,131). LPS is hence highly immunogenic and if 
present inside the body, especially in humans. High levels of LPS in the blood 
can be lethal through the severity of the immune response. This phenomenon 
is called septic shock. 
Since CT is so potent at eliciting an immune response at mucosal surfaces it 
has been subjected to extensive investigation as a vaccine adjuvant (132). An 
adjuvant is a necessary component in vaccines that are based around only a 
few components of a pathogen often called subunit vaccines. The components 
alone often lack a strong immune stimulatory property that the adjuvant 
instead can contribute with (133). To avoid adverse effects CT has been 
modified in several ways and sometimes the subunits of CT have even been 
used individually (132,134-136). It has been concluded in animal studies that 
the adjuvant effect of CT is dependent on expression of GM1 or GM1-related 
glycolipids in the dendritic cells (137). Why the adjuvant effect has this 
dependency is unclear and this expression dependence is exclusive to 
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dendritic cells. Possibly the specific uptake via GM1 could facilitate the 
necessary pathway for eliciting a response. Alternatively, GM1 is so 
abundantly expressed on GM1-competent dendritic cells and the lack 
therefore effectively renders GM1-incompetent cells insensitive to the dose 
used. So far the only licensed vaccine with CT components in it is Dukoral, 
used to vaccinate against cholera (138). In addition to inactivated bacteria this 
vaccine also contains the CTB subunit. 
 
VACCINES AND TREATMENTS 
Currently there are two licensed vaccines against cholera; Dukoral and 
Shanchol. Both vaccines are oral solutions that give 50-75 % protection after 
immunization. However, booster doses of the vaccines or reoccurring V. 
cholerae exposure is required to maintain protective antibodies over long 
periods of time. Both Shanchol and Dukoral are vaccines based on bacterial 
components from inactivated V. cholerae. The main differences between the 
vaccines are that Dukoral has only bacteria from serogroup O1 and 
recombinant CTB, whereas Shanchol contains both serogroup O1 and O139 
(138). The idea behind adding excess CTB to Dukoral is that this will ensure 
a strong antibody response to CTB and thus block CT’s ability to bind to 
cells. This way, a strong response to CT can be raised without having the 
detrimental effects of CTA. Neutralizing antibodies against CT in the intestinal 
lumen are the main protective feature of the vaccines and natural immunity 
(138,139). Both vaccines are based on 3 different V. cholerae stains of classical 
and El Tor biotype and of both Inaba and Ogawa serotype, ensuring a 
response to the two types of LPS (138,140).  
However, since a large part of the population in endemic areas lack 
vaccination the need for acute clinical treatment is urgent. Treating cholera 
can often be done using quite inexpensive oral rehydration therapy (ORT) 
consisting of clean water with salt and glucose (1,141). Addition of amylase-
resistant rice starch can further increase the effectiveness of the ORT and 
shorten the period with watery diarrhea as well as reducing the loss of fluid. 
It is believed that this effect comes from increased colonic fluid uptake due 
to increased osmolality from the starch (142). Another possible theory is that 
rice starch is able to inhibit CT uptake, thus ameliorating the diarrheal 
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response upon infection. This theory could also explain why treatment with 
ORT and amylase-resistant rice starch shortens the duration of the diarrhea, 
as well as the reduction in fluid loss.  
In hospitals rehydration can also administered intravenously using Ringer's 
lactate. Administrations of antibiotics can also be necessary to improve 
recovery in cases of severe diarrhea, although usage should be limited to avoid 
emergence of antibiotic resistance. Implementation of these relatively simple 
treatments has taken the case-fatality down to well below 1%, whereas 
untreated cholera can have a mortality rates of 50% or more (1,4). 
As the case fatality rate is so low in hospitals it is challenging to further 
improve the survival rate in that setting. Treatment could however be 
improved from a morbidity-point, by trying to decrease the fluid loss or 
shortening the time with acute diarrhea. For such an endeavor a CT-binding 
agent might be employed to inhibit cellular uptake of CT. One aim of this 
thesis was focused on evaluating such inhibitors in various model systems of 
cholera. These studies were intended as a first step towards the possibility of 
an additive in ORT to reduce morbidity. Previous trials using immobilized 
GM1 on charcoal showed some promise in this regard but that particular 
method proved too inefficient (143).  
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GLYCOSYLATION 
A large number of pathogens and toxins are dependent on host glycans for 
binding, and CT is no exception. It is therefore key for understanding CT to 
know the basic mechanisms and patterns of expression with regards to 
cellular glycosylation. This section will aim at creating a basic understanding 
for glycosylation in mammals. 
Glycosylation can be described as a one of several post-translational 
alterations to proteins, enabling a much greater diversity than the unmodified 
proteome would be able to achieve. Glycosylation is often more long-lived in 
nature compared to other modifications such as phosphorylation and often 
last for the majority of the protein lifetime. As the name implies glycosylation 
refers to the addition of sugars to a protein (or lipid discussed below). The 
main types of sugars used for glycosylation in mammals are mannose, glucose 
and galactose and the amino sugars N-acetyl-glucosamine (GlcNAc) or N-
acetyl-galactosamine (GalNAc). These sugars are commonly used to build up 
chains of sugars called glycans (144-146). The Glucose-Galactose-based 
glycans are often further modified with additional sugars such as sialic acid or 
fucose. Sialic acid is clearly different from the other sugars by having 9 instead 
of 6 carbons and in non-human mammals comes in both Ac- and Gc-forms 
(147). Fucose is also somewhat special since it only occurs naturally in the 
steric L-form, as opposed to the other sugars that have the D-form. Other 
types of glycans also exists based around sugars like hyaluronic acid or those 
consisting of just one sugar like O-GlcNAc-modifications, but these will not 
be further discussed in this thesis (144,145).  
Glycosylation is carried out by enzymes called glycosyltransferases, which link 
sugars via hydroxyl groups on sugar backbone carbons. Most 
glycosyltransferases specifically join exact carbons of two specific sugars 
adding an important layer of specificity in the glycan synthesis. Furthermore, 
glycosyltransferases also have specificity for the type of glycan chain it can act 
upon so that only the intended glycans are further modified. However, several 
glycosyltransferases might be able to modify the same substrate glycan chain. 
Therefore, there is a competition in the process of building complex glycans 
dependent on the respective affinities for the substrates and the efficiency of 
modification. This commonly leads to a mix of end products, resulting in 
varying degrees of completion for complex glycans. As there is no template 
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for glycosylation, as there is for protein synthesis, this is expected (145,146). 
In addition, external and internal physical, chemical and enzymatic onslaught 
can alter the finished glycans over the lifetime of the glycoprotein. Asides 
from being attached to proteins, glycans can also be secreted to act as food 
for commensal bacteria or decoy receptors and barriers against pathogens. 
 
N- AND O-LINKED GLYCOSYLATION 
As mentioned above CT relies on binding to glycans for internalization and 
intoxication. Glycans are linked to proteins via the terminal nitrogen or 
oxygen on amino acid side chains. Nitrogen-linked glycans or oligosaccharides 
are only performed on asparagine and is called N-linked glycosylation. O-
linked glycosylation as the name implies is performed on the terminal oxygen 
of serine or threonine (146,148). The enzymes required for N- and O-linked 
glycosylation are very different and will result in different types of glycans.  
N-linked glycosylation always starts in the endoplasmic reticulum by attaching 
a prefabricated oligosaccharide with two core N-acetylglucosamines with nine 
mannoses and three glucoses (Fig 3A). Three glucoses and one mannose 
moieties are quickly cleaved from the oligosaccharide, while the remaining 
glycoprotein is transported to the Golgi for further trimming of the mannose 
moieties and extensions of other sugars. N-linked oligosaccharides are often 
divided into three main types: high mannose, complex and hybrid (Fig 3B).  
High mannose as the name implies mainly contain mannoses and lack further 
glycosylation. The complex variants have extensively reduced the mannose 
content and display a wide variety of different sugars usually in a branched 
fashion. N-linked glycosylation exclusively occurs on sites with a consensus 
sequence (Asn – XXX – Ser/Thr). In contrast, no such sequence has been 
identified for O-linked glycosylation (149). O-linked glycosylation is performed 
one sugar at the time gradually building branched or non-branched glycans.  
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Figure 3. Mammalian N-glycosylation. A) Schematic drawing of the start glycan in N-
glycosylation. B) Examples of the three types of N-glycans; high mannose, hybrid and complex, 
as seen from left to right. R represents attachment to asparagine on a protein chain.  
 
LIPID GLYCOSYLATION 
The hydrophilic head-group of lipids can also be glycosylated similar to side 
chains on proteins. As for proteins the various roles that these glycan 
modifications play are too diverse to fully cover in this introduction. 
However, the glycolipid GM1 is commonly known to bind CT with a very 
high affinity and act as a functional receptor for CT. The natural and more 
constructive role of GM1 in the human body is not fully understood but it has 
been shown to facilitate neuronal survival, differentiation and proliferation 
(74). Other glycolipids have been shown to be involved in cellular adhesion 
and cell signaling. It is not uncommon that glycolipids are present in 
extracellular fluids and blood group antigen glycolipids are abundantly found 
in serum. Several glycolipids also acts as toxin receptors and anchors for 
bacterial adhesion (74,150-152). In this section I will mainly focus on 
describing the glycosphingolipids (GSLs) since these are of well-documented 
importance for CT binding and intoxication. All GSL glycosylation starts by 
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glucose being O-linked to a ceramide head group. The GSLs are then further 
glycosylated to form more complex glycans, either branched or non-
branched. An important subclass of GSLs is gangliosides to which GM1 
belongs. All gangliosides use the lactose-ceramide as a starting substrate and 
are made by adding galactose and glucose together with branching sialic acid/s 
(in most cases). Although CTB has the strongest affinity for GM1, other 
gangliosides also have a weaker affinity such as GM2 and GD1a to mention a 
few (54). In the absence of GM1 those other binders might act as receptors 
for CT. 
 
Figure 4.GM1 and GM1-related gangliosides. Schematic drawings of A) GM1a, B) GM1b, 
C) asialo-GM1 and D) GM2. The blue glucose is attached to the ceramide in the cell membrane.  
Important to mention is that the “M” in GM1 refers to the fact that this 
ganglioside is mono-sialylated (as opposed to “D “and “T” referring to di- and 
tri-sialylation) of which there are two forms GM1a and GM1b (Fig 4A-B). 
GM1b has a sialic acid on the terminal galactose and does not bind well to 
CTB whereas GM1a has the sialic acid on the core galactose and binds 
strongly to CTB. When GM1 is mentioned in this text it infers to GM1a unless 
otherwise stated. As mentioned above the CTB-GM1 interaction is highly 
dependent on the two-finger grip provided by the terminal galactose (the 
index finger) and the core sialic acid (the thumb) shown by the fact that asialo-
GM1 and GM2 (Fig 4C-D) have severely impaired ability to bind CTB. The 
nature of this binding was first elucidated in a crystal structure of CTB in 
complex with GM1. From the structure it is also clear why the sugar 
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orientation in GM1b is not able to mediate sufficient binding for CTB, since 
the terminal placement of sialic acid would disable the two finger grip (Fig1) 
(53,153).  
 
FUCOSYLATION AND HBGA SYNTHESIS 
Fucosylated glycans are common in the human intestine, especially in the form 
of histo blood group antigens (HBGAs) (154). Interestingly, blood group O 
expression has been implied to increase sensitivity to cholera (17,155). 
Addition of fucose to glycans is performed by fucosyltransferases (FUTs) using 
GDP-L-fucose as donor. In humans thirteen FUT genes have so far been 
identified (156,157). 
The known human FUTs catalyze a(1,2)-, a(1,3/4)- and a(1,6)-fucosylation. 
The FUTs responsible for making a(1,2)- and a(1,3/4)-linked fucose do so 
terminally or sub-terminally on substrate glycans, whereas a(1,6)-FUTs 
catalyzes core fucosylation at the innermost moiety of N-glycans. Core 
fucosylation is crucial for antibody function as it regulates antibody interaction 
with complement and Fc-receptors, but does not generate CT-binding glycans 
(156,158). The alpha-linkage is formed between two hydroxyl groups from 
carbons of the same spatial orientation resulting in a same-side, bond as 
opposed to the beta-linkage where the bond reaches from one side of sugar 
1 to the other side of sugar 2. This enables beta-linkage to produce straight 
chains of sugars like those seen in cellulose, whereas alpha-linkage chains 
results in a spiral shape (159).  
Terminal and sub-terminal FUTs are crucial for making HBGAs like the ABO- 
and Lewis-system glycans. Fucosyltransferase 2 (FUT2) is responsible for 
adding terminal 1,2 fucose on terminal LacNAc forming a blood group O 
glycan. Blood group O then acts as the precursor for blood group A and B 
glycans (Fig5) (160). FUT2 alleles have a high degree of diversity in humans 
and dysfunctional variants, and about 20% of the European population are so 
called non-secretors (161,162).  FUT2, also call the secretor gene, is 
expressed in all mucosal tissues (160). Secretor negative individuals does not 
lack secreted glycans, as the name would suggest, but lack more complex 
LacNAc-based structures than Lewis A and Lewis X on core 1 and 2 chains 
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(160). Normally the FUT2 enzyme will be able to act upon virtually all LacNAc 
chains and thus inhibit the formation on Lewis X and A, and instead the most 
common types found in a blood group O positive individual are Lexis Y and 
B (Fig 5). The LacNAc chains may also only go down the path of making blood 
group A and B (160). This is done by adding a terminal galactose or GalNAc 
respectively, inhibiting further addition of sub-terminal fucose. However, 
Lewis Y and B may be acted upon by the blood group A and B enzymes 
resulting in ALewis Y/B or BLewis Y/B (Fig 5) (160).  
The Lewis system glycans can be made from two forms of LacNAc called type 
1 and 2 chains. Type 1 chains have a 1-3 linkage between the galactose and 
the GlcNAc whereas type 2 has a 1-4 linkage. This might seem like a small 
difference but has a dramatic impact on how the sugars are presented 
sterically. By default, a type 1 chain can only accept a subterminal (attached 
to the GlcNAc) fucose in a 1-4 linkage and this then becomes Lewis A, or 
Lewis B if a terminal fucose (attached to the galactose) was already attached. 
The same is true for fucosylation of type 2 chains but then the products are 
Lewis X and Y, which are the enantiomer counterpart to Lewis A and B 
respectively (163-165).   
In the process of making HBGAs several FUTs are involved and they all have 
slightly different preferences for substrates. FUT7 and 9 can also fill the role 
of FUT3 in making Lewis Y/X, primarily acting on terminal LacNAc whereas 
FUT3 can act also on subterminal LacNAc. FUT7 only has the ability to 
fucosylate sialylated LacNAc, enabling further diversity but also regulation at 
the protein level of the expressed glycome (165,166). Therefore, the 
sialylated version of Lewis X is closely linked to FUT7 expression and 
detected in high amount on neutrophils. Sialylated Lewis X is also expressed 
at a low level in the human small intestine but other HBGA are more 
abundant compared to GM1 (Fig 5) (157,163,165,167). In fact, expression of 
GM1 in human small intestinal cells is very low (168). In addition, there is, as 
mentioned above, a strong correlation between blood group O and severity 
of cholera disease symptoms in humans. Hence, although GM1 is by far the 
most effective receptor for CT the HBGAs may be of importance due to the 
abundance in the small intestine. A schematic representation of HBGAs 
relevant to binding to CT can be seen in figure 5.  
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Figure 5. Common intestinal HBGAs. Schematic drawings of Lewis and ABO-antigens 
found in the human intestine. The difference between core 2 and 1 is the beta1-4 or beta1-3 
linkage between the galactose and GlcNAc forcing the GlcNAc-liked fucose into the alpha1-3 
or alpha1-4 linkage respectively. 
 
GLYCOSYLATION IN THE INTESTINE 
As on all cells in the human body the intestinal barrier cells are heavily 
glycosylated. On the apical side several membrane-bound mucins are located 
effectively creating a physical barrier for the cells in addition to the secreted 
mucin layer discussed below (169,170). Both lipids and proteins are 
glycosylated with a broad spectrum of glycans serving multiple functions (171). 
Some glycans or glycoproteins, such as mucins, are also secreted into the 
intestinal lumen. All forms of glycans play different roles but in general they 
add an extra layer of complexity and diversity to the proteome and lipidome. 
This fact enables cells to deeply specialize and efficiently manage protein and 
lipid functions (171). More concrete examples of functions related to 
glycosylation are half-life extension, conferred by steric hindrance for 
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enzymes or glycans acting as the ligand in cell surface receptor interactions 
(146).  
In the human intestine a significant proportion of the glycans contain fucose, 
and HBGAs are abundantly expressed (172-176). Several symbionts have 
adapted to this and carry fucosidases to efficiently extract nutrition from host-
produced glycans, or fucose sensing proteins to adapt to the host milieu upon 
infection (177,178). This intricate and complicated interplay between 
microorganisms and the human host depend significantly on IL-22 production 
by immune cells sensing the bacterial presence and composition. IL-22 is then 
sensed by the epithelial cells and induces the production of more fucosylated 
structures (179). The commensal bacteria also seem to be able to influence 
the glycosylation via secreted metabolites sensed by the host (174).  
This enables a crosstalk between organisms without the need for physical 
contact. This mode of communication is necessary since direct bacterial 
contact with the epithelium and the underlying immune cells would most 
likely trigger a severe immune response (35,180,181). To this end the mucus 
layer in the small intestine acts as an accumulation zone close to the crypts 
for antimicrobial peptides and IgA. This accumulation prevents bacteria 
reaching the epithelium but allows the mucus to be porous enough for 
efficient nutritional uptake (180). This highlights that the immune system, 
epithelium and microbiota all actively interact to maintain a delicate balance 
beneficial for all parties (174,181).  
 
MUCINS 
The whole gastrointestinal tract is lined with a mucus layer protecting the 
underlying cells from dehydration and the environment. The mucus in the 
small intestine is mainly made up of Muc2 and is differentially organized in the 
different parts of the intestine (180). Colon has an inner and outer mucus 
layer where the inner layer is firmly attached to the cells, while the outer 
layer is more loosely packed and is more permeable to bacteria. This two-
layer system ensures that the epithelial layer is protected from direct contact 
with the extensive colonic flora. The small intestine has a much lower 
bacterial burden and only produces a mucus layer corresponding to the 
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colonic outer layer (182). The mucus layer is constantly replenished via Muc2 
release from goblet cells. Muc2 is heavily glycosylated with about 80% of the 
total weight from the added glycans (183,184). Muc2 is expressed in a gradient 
from duodenum, with lowest level, to colon with the highest (180,185). The 
high density of glycans on Muc2 enables the binding of a lot of water effectively 
forming a protective gel. Muc2 is so large that it is polymerized and folded 
inside the goblet cells until release. When secreted the polymer quickly 
expends forming a net-like sheet with a diameter several times bigger that the 
goblet cell (183,186). Although Muc2 has N-glycosylation the vast majority of 
the glycans are O-linked and several of the glycan chains include HBGA 
moieties (183,184,187). As mentioned above the O-glycans fill several 
functions like protecting the protein backbone and binding water to create 
the gel texture of mucus. Another function is that the glycans provide 
nutrition for commensal bacteria, with glycosylation being a result of crosstalk 
between the host and commensals (184,188). Muc2 also acts as a physical 
barrier and habitat for commensal bacteria having the potential, together with 
other secreted glycoproteins like IgA, to modulate colonization and to inhibit 
harmful bacterial and toxin binding to epithelial cells. As discussed below, 
glycans in human breast milk can also fill this function, likely acting in synergy 
with secreted maternal IgA antibodies to prevent infection and intoxication 
in infants.  
 
FUCOSYLATION IN THE IMMUNE SYSTEM 
Many glycan structures important for cellular interactions contain fucose such 
as fucosylated glycans interacting with selectins. Selectins catch and enable 
rolling of leukocytes on endothelial surfaces in inflamed areas, leading to 
extravasation of immune cells from blood into the tissue (189,190). The 
selectins primarily interact with sialyl-Lewis X on glycoproteins such as CD44, 
where the relatively low affinity between glycan and protein allows for rolling 
to occur slowing down the leukocytes traveling in the blood stream without 
damage. Although cell adhesion to endothelium is the most studied function 
of fucosylation, it also plays a key role in other areas such as in the 
differentiation and linage plasticity of a several of immune cells. One example 
is core fucosylation in the Fc domain, which is important for the function of 
antibodies in antibody-dependent cell-mediated cytotoxicity (163).  
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CD44 expression is not limited to classical immune cells but is also expressed 
on stem cells in the intestine. In fact, the Kohler group recently published a 
paper showing an interaction between CTB and CD44(191). Mass 
spectrometry analysis of eluates from CTB pull-down experiments indicated 
that CD44 could act as a receptor in the colonic cell line T84. Further 
immunoprecipitation experiments confirmed an association between CD44 
and CTB (191). Another promising CTB-binding candidate from that paper 
was CEACAM5 (also called CD66e), which has also been shown to have 
Lewis X glycans attached (192). As for CD44, CEACAM5 was proven to 
associate with CTB. 
 
GLYCANS IN HUMAN MILK AS TOXIN INHIBITORS 
As discussed above, human breast milk contains large amount of IgA 
antibodies effectively protecting infants and breast feeding children from 
various pathogens such as V. cholerae (127-129). Brest milk is also protective 
for a different reason, namely that formula has to be mixed with water, and if 
not sterilized properly this water might harbor pathogens. Breast milk also 
contains several types of molecules other than antibodies that might affect 
pathogens, such as glycans. Therefore it is hard to assess the impact of 
maternal antibodies alone (193-196). However, association studies can be 
performed between antibody levels and risk of disease (128,129). Such studies 
cannot confirm any hypothesis but together with other functional studies IgA 
is proven to prevent infection and intoxication (197,198). 
As stated above fucose plays a major role in bacterial colonization of the large 
and small intestine. Human milk contains a lot of different oligosaccharides 
(HMOs) that are fucosylated to a large degree (199). The individual HMO 
composition correlates with the intestinal microbiota in breastfeeding infants 
and clear differences in colonization can also be seen compared to formula-
fed infants (194,200). The HMO composition also seems to affect the 
microbiota of the milk itself influencing the infant gut colonization (200,201). 
Although heterogeneously expressed HMOs are also able to bind to several 
virulence factors of pathogenic bacteria and viruses, potentially inhibiting 
those from infecting infants (190,195,196,199,202,203). Most formulas are 
based around cow milk, which contain few fucosylated oligosaccharides. The 
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addition of 1-2 linked fucosyllactose (2'FL), the major fucosylated HMO, to 
regular formula significantly normalized the levels of pro-inflammatory 
cytokines seen in formula feed infants compared to breastfed (190,203). 
Another example of the immune systems impact is the direct link seen 
between the dendritic cell marker DC-SIGN and HMOs, where fucosylated 
HMOs effectively protecting dendritic cells from infection by inhibiting 
pathogen adhesion to DC-SIGN (204). This suggests that the fucosylated 
HMOs not only modulate bacterial colonization and prevent pathogen 
establishment, but also regulate proinflammatory cytokine release. To 
complicate this even further the composition of HMOs varies between 
mothers and non-secretors lack the major HMO of secretors, 2'FL. Instead 
the major HMO in non-secretors is lacto-N-fucopentose II (LNFP II), where 
fucose is linked via 1-4 linkage and hence independent of FUT2 (196,199).  
All the heterogeneity with regard to HMO composition highlights the 
impossibility of having an innate mechanism that can confer protection 
towards all pathogens. In fact, it is likely that some of the HMO glycans can 
facilitate pathogen infection when attached to lipids and proteins. Humans in 
different physical or temporal locations are subjected to different floras of 
pathogens. This would assert varying selection pressure for glycan expression. 
This theory would explain why humans have such a diverse glycome that also 
has a geographical/ethnic component (196,205).  
Taken together human breast milk likely contains several molecules, like 
HMOs and IgA, that are effectively promoting normal gut flora as well as 
inhibiting pathogen colonization and aid in immune system development 
(194,200,201,204,206). HMOs are also able to bind and thereby reduce the 
effect of various bacterial toxins and viruses (207-210). This proposed 
protective mechanism would then fall under the innate immune system 
conferring some protection against yet not encountered pathogens. HMOs 
can be viewed as a complement to IgA, but IgA is likely to confer a more 
direct and effective neutralization of toxins and viruses.  
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ALTERNATIVE RECEPTORS FOR CT 
Although it is quite clear that GM1 can act as a receptor for CT and will do 
so efficiently, there are several findings indicating that other receptors might 
also be involved in CT intoxication. The main findings include a clear 
association between blood group O carriers and cholera severity in addition 
to the fact that GM1 is so lowly expressed on the epithelial surface in the 
human small intestine (16,168,211). I will here attempt to make an overview 
of previous work showing that CTB also binds other ligands than GM1 and 
create a context around the development of the “GM1-dogma”.  
It has long been known that the close relative to CTB, LTB has a more 
promiscuous binding pattern regarding glycolipids (212-214). LTB was also 
shown to bind to glycoproteins in the rabbit small intestine. In contrast to 
LTB, CTB was not shown to bind to proteins. However, this might be 
explained by the detection method used. Toxin binding to the protein fraction 
from the rabbit intestine was determined by its ability to block CTB/LTB 
binding to GM1-coated ELISA plates. This approach would effectively ignore 
all other possible biding sites on CTB/LTB (213). Later this study was 
repeated on human intestinal tissue with similar results and again with a strong 
GM1 bias for detection of protein-CTB/LTB interaction (214). In fact, since 
the identification of GM1 as a major ligand for CTB most detection of CTB 
binding has been assessed using GM1 in a unfortunately biased way 
(33,72,78,215-221). It is therefore clear, all be it in hindsight, that the 
conclusion that CTB exclusively bind to glycolipids was predicated on 
experiments that were unlikely to come to another conclusion given the 
extreme affinity in the CTB-GM1 complex.  
Furthermore, recent (and not so recent) papers have shown a GM1-
independent binding of CTB to both cells and in biochemical assays  
(62,63,222). As mentioned above, this binding has primarily been mediated via 
fucose on HBGAs that can occupy a distinct site from the GM1-site on CTB. 
This effectively means that there is potential for CTB being bound to both 
GM1 and HBGAs simultaneously (61-64,207). In fact, the CTB binding to cells 
has not always been found to correlate with or depend on GM1 or glycolipid 
expression (58-60). If this GM1-independent binding is always mediated via 
the noncanonical lateral HBGA-binding site, or if the canonical site is also 
involved was not elucidated in these publications. 
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There are several publications over the last few years both indicating and 
proving that HBGAs specifically bind to CTB (62,63,222).  A relationship 
between CT binding and the A glycan of the ABO-system was identified in 
the late eighties (223). The same group later showed that the blood group A 
carrying mucus, but also A-negative could inhibit CT binding (224). Later it 
was also shown that both LTB and a CTB/LTB hybrid could interact with 
HBGAs (225-227). More evidence has been published using more defined 
glycans showing that both classical and El Tor CTB binds Lewis Y and all ABO-
glycans (61-63). This HBGA-link also has functional evidence to support it, as 
human enteroids that are blood group A-positive are better protected against 
CT induced cAMP than A-negative cells (155). This, and other findings have 
been put forward as the most plausible explanation for the more severe 
cholera seen in blood group O individuals (17). A-glycans could be considered 
as decoy receptors for CT, preventing effective uptake via the canonical 
pathway for CTA. Due to similarity and experimental binding data, blood 
group A and B are considered to confer equally good protection, although 
this has not been experimentally tested in enteroid cultures (62). To date, 
there is no conclusive data regarding the effect that the Lewis glycans have on 
CT toxicity and more investigation is needed to fully understand the 
functional role of ABO-glycans in CT-mediated intoxication.  
Given the substantial knowledge today regarding alternative ligands for CTB 
the scientific community should stop using CTB as a specific marker for GM1. 
An example of this misuse outside the primary field of cholera is evident in 
the field of neuroscience. CTB is commonly used as a marker for GM1 in 
many tissues like CNS. However, Lewis X is also highly expressed in the CNS 
complicating interpretations of CTB binding in the CNS. What can be said 
with confidence is that both Lewis X and GM1 readily binds CTB making CTB 
as a marker for GM1 highly unreliable (64,228-230).  
In conclusion, non-GM1 binding of CT has been known for a long time, yet 
GM1 has not been properly questioned as the sole functional receptor. 
Therefore, functional experiments investigating the role of HBGAs (and/or 
other glycans) in CT toxicity would be valuable additions to the otherwise 
vast pool of knowledge about CT. My hope is that the work in this thesis will 
shed some more light onto the matter and also further spread the knowledge 
about alternative receptors for CT. 
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ALTERNATIVE SELECTION FOR CTXF 
A recent paper has described that CT can act as a bactericidal suggesting that 
CT production can generate a growth advantage for V. cholerae during 
intestinal infection. CT is then able to bind GM1-like glycans expressed by 
other bacteria such as Campylobacter jejuni. Interestingly, the same paper 
showed that the CTB-binding in the chicken small intestine is partially fucose-
dependent and that fucosylated structures together with GM1 make up the 
CTB-binding potential (231). This important finding highlights the possibility 
that CT might have been selected for in inter-bacterial competition rather 
than, or in combination with, the effect that CT clearly has on the host. This 
new theory could explain why it is beneficial for V. cholerae to keep the CTXF 
phage also in the environment. Environmental V. cholerae is often found on 
water dwelling organisms such as shellfish and alga but also insect larva. A 
possible symbiotic relationship between V. cholerae and crustaceans has 
therefore been proposed (232). The theory was that CT produced in the gills 
would help the animal to adapt to the change in osmotic pressure when 
moving into more saline rich water. Meanwhile the bacteria would gain access 
to larger amounts of nutrition from the surrounding water. Alternatively, the 
biofilm of the bacteria could protect the shell from degradation in low pH. 
However, this area needs more investigation. A more likely reason for 
colonization and symbiosis could be that V. cholerae can use chitin as a carbon 
and nitrogen source, in return forming a pH resistant biofilm around the host 
shell (21,232,233).  
Together these findings suggest a possibility that CT is not only a virulence 
factor in human infection but also plays a role in the environmental survival 
of V. cholerae. Further investigation into this topic could help us understand 
why the CTXF phage is selected for, not only in the infected human gut, but 
also in the environment.  
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CLASSICAL MODEL SYSTEMS OF CHOLERA 
IN VIVO 
One of the major challenges in studying cholera is the fact that V. cholerae is 
an obligatory human pathogen. The main “natural” infection model uses infant 
mice infected just after birth. The bacteria is then able to colonize the small 
intestine and induce watery diarrhea similar to that seen in human cholera 
cases (234). However, for a yet unknown reason, a few days after birth the 
mice become no longer susceptible to infection.  
Other infection models exist for V. cholerae. One example is the ligated loop 
model, where loops of the intestine is surgically exposed and tied of with 
sutures. The loops are then injected with bacteria to mimic an infection. 
However, this method raises ethical concerns since animals are often woken 
from anesthesia after surgery to accommodate for the several hour long 
incubation before loop harvest. The advantage of this model is the ability to 
assess the exact amount of fluid secreted in response to CT (90). The loops 
can also be used to test the CT alone since it will readily elicit a forceful 
response in most mammals including mice, rabbits, pigs and dogs (88,235-
238). Another in vivo method is also available where streptomycin resistant V. 
cholerae is used to infect mice treated with streptomycin. The infection is 
enabled by clearing a niche via the streptomycin challenge and unlike human 
infection this model is independent of TCP (239).  
 
CELL LINES 
Human cell lines derived from various cancers (primarily colon cancers) have 
also been used extensively to study the effects of CT. This has the benefit of 
using tissue from the only species where the disease is observed, which is 
more practical and better from an ethical perspective. However, cell lines 
derived from cancers are not always recapitulating the original tissue 
correctly. In addition, V. cholerae primarily infects and acts upon the small 
intestine, not the large intestine (88,240,241). Patterns of protein expression 
and (importantly for CT) glycosylation have been known to be quite different 
in transformed cell lines compared to primary tissue (242-244). It has also 
been shown that growing cells with different concentrations of glucose greatly 
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affects glycosylation and protein expression. In fact most cell culture media 
contains glucose well above the normal blood sugar levels, while it is known 
that elevated blood sugar has a number of effects (242-244). There are culture 
mediums with glucose levels corresponding to normal blood sugar levels, but 
it requires more frequent media change due to nutritional depletion.  
The cell lines also fail to recapitulate the diversity of cell types in the primary 
tissue. Some are able to differentiate into similar morphology and function as 
only one or a few cell types of the primary tissue. As an example, confluent 
Caco2 cells will over time form tight junctions and microvilli and thus closely 
recapitulate the intestinal enterocyte. However, other cell types such as 
goblet cells, Paneth cells and enteroendocrine cells are lacking. Using cells for 
experiments always runs the risk of missing crucial aspects of the primary 
tissue for all the reasons listed above.   
 
ENTEROIDS AS AN INTESTINAL MODEL 
To combat these general problems, establishment of protocols to culture 
primary intestinal stem cells have been the priority for several groups. In the 
past 5-10 years several groups have been able to establish intestinal cell 
cultures from primary cells. Some have also used pluripotent stem cells and 
differentiated them into cells very much like intestinal stem cells - here called 
organoids. Others have isolated crypts from small intestinal biopsies and 
established stem cell cultures - here called enteroids (245). We have only 
used enteroids and all further discussion will be regarding such cultures. The 
idea with these cultures is to recapitulate most of the complexity of the 
mucosal barrier including several cell types and functions. 
Indeed, the cultures show a much more diverse phenotype than cell lines with 
all the major cell types seen in the primary tissue and a mucus layer etc. 
(246,247). Using enteroid cultures to model V. cholerae infection is most likely 
as close as we can get to the natural human infection without actually infecting 
health volunteers. The system also offers the possibility of genome editing to 
knock out or knock in different glycosylation enzymes and thus study the 
effect of the glycome in cholera pathogenesis.  
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Enteroids are not transformed and are therefore very much like primary cells. 
For them to survive in culture several requirements needs to be met. Firstly 
a cocktail of growth factors such as epidermal growth factor and noggin needs 
to be added to the culture media to facilitate stem cell growth and renewal 
as well as maintenance of other cell types (245). To help the cells remain in a 
stem cell state the medium also contains the growth factor Wnt3A. By 
removing the Wnth3A from the medium the cells fully differentiate and stem 
cells are lost (245,246).  
Another requirement is a 3D support in form of a gel for the cells so they 
can maintain their spatial relationship to each other. The gel might also 
contain hormones helping the cells to grow properly. The cells form small 
spheroids in the gel that grow more complex with time resembling miniature 
intestines with crypt-like spikes. In this culture state the apical side of the cells 
face the lumen so only the basolateral side is exposed to the outside. To study 
effects if microbiota and other intestinal exposures the spheroids need to be 
broken up and seeded in collagen-coated trans-well inserts. In the trans-wells 
the basolateral side will attach to the collagen and form a monolayer of cells 
with the apical side exposed for treatment. Several groups have recently used 
this culture system for both CT challenge and co-culture with macrophages 
seeded on the basolateral side. Using this system it can be observed that 
macrophages extend protrusions though the confluent enteroid monolayer in 
response to an apical bacterial infection and that enteroid cells readily 
respond to CT (155,246,248,249).  
This is only the first step in fully recapitulating the diversity of cells present in 
the small intestine. To have a species specific model of the intestine would be 
of immense benefit for researchers both trying to find cures for intestinal 
diseases, but also for the general understanding of cellular functions such as 
mucus secretion and nutrient uptake. It would also be uniquely possible to 
study the full pathogenesis of V. cholerae in a co-culture model of enteroids 
and immune cells.  
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AIMS 
This thesis has two connected but distinct aims both addressing CT 
intoxication of the cells in the human intestine. They are based around 
exploration of noncanonical binding by CT to fucosylated glycans with the 
goal of understanding how and if these novel receptors act to facilitate CT 
intoxication or counteract it as decoys. 
The specific aims of this thesis are: 
- To characterize and evaluate the binding and the functional potential of 
fucosylated receptors for CT on epithelial cells in human and mouse small 
intestine. This also includes investigation of the role of the previously 
described GM1 or GM1-like receptors. 
- To evaluate the effectiveness of polymer-linked fucose and/or galactose in 
inhibiting CT binding to intestinal cells and preventing CT-mediated 
intoxication. 
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MAIN METHODS AND ETHICAL 
CONSIDERATIONS 
Working in a lab focused on intestinal immunity and vaccines, it was natural 
to use methods like flow cytometry, enzyme-linked immunosorbent assay 
(ELISA) and animal challenge models. I have used these methods extensively 
throughout the thesis, but several other methods have also proved very 
useful. Here I will go through the main methods I have used while studying 
with CT. I will also give arguments for and against using the methods as well 
as why they were chosen. Some methods used in the papers will not be 
discussed here since I did not perform them. One clear example of this is the 
synthesis and biophysical characterization of the fucose polymers. 
 
FLOW CYTOMETRY 
Without a flow cytometer this entire thesis would not have been possible. It 
is truly the backbone method of this work. Flow cytometry is in short a tool 
to investigate the presence and level of expression of any cellular component. 
Flow cytometry is used primarily for assessing proteins and glycans but also 
nucleic acids, ions and lipids. This is useful for characterizing cell types and 
how they are affected by various conditions and treatments. In this thesis I 
have primarily used flow cytometry to identify cell types and assess the 
relative binding of CTB to those cells.  
A flow cytometry experiment starts by making a single cell suspension of the 
tissue or cultured cells of interest, to stain the cells with antibodies against 
various cell markers. The antibodies or other cell binding molecules have 
covalently liked fluorochromes used for detection in the flow cytometer. The 
stained cells are aspirated into the flow cytometer where they are made to 
pass one by one through a set of laser beams. The laser beams excite the 
fluorochromes and the emitted light is recorded. By using a set of different 
fluorochromes and light filters the expression of several markers can be 
assessed on each cell simultaneously. The ability to accurately assess multiple 
markers for both presence and level of expression is very useful and not 
possible with many other methods.  
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A method like fluorescence microscopy will give you similar capabilities but 
only with a few markers at the same time and has low resolution with regards 
to expression level. In flow cytometry cells are stained in a single cell 
suspension increasing the accuracy with regards to expression level compared 
to fluorescence microscopy. The reason for this is that the suspended cells 
are completely and homogenously surrounded by the staining liquid. This is 
not the case for tissue or fixed cells stained on a glass slide for microscope, 
since the cells are less likely to have equal access to the staining liquid. Due 
to this a substantial discrepancy in staining intensity is not uncommon.  
One of the disadvantages of flow cytometry is that you often have problems 
with auto fluorescent cells and contamination of dead cells and small debris. 
This is especially the case for intestinal tissue whereas most peripheral blood 
mononuclear cells have low and well defined autofluorescence signals. 
Autofluorescence is not always a problem and can be avoided by not using 
the fluorochromes most affected for the autofluorescent cells. Using live/dead 
stains and excluding dead cells in the analysis helps as dying cells will not have 
an intact cell membrane and unspecific staining of intracellular proteins can 
occur. Relating to the live/dead-problem is the fact that the cytometer only 
records something called events or cell-like objects. Events are thought to be 
mostly cells but there is no clear way for the machine to distinguish cell-like 
objects from real cells. In this regard microscopy has a distinct advantage in 
enabling the operator to exclude suspected or confirmed non-cell objects 
from the subsequent analysis. 
All considered the benefits of flow cytometry far outweigh the drawbacks 
making the choice easy to use it as the backbone method.  
 
ANIMAL STRAINS 
The work in this thesis has only used mice of the commonly used inbred C57 
black6/J main stain. These mice are also referred to as wild type (WT) in the 
following text the particular stain was chosen as it has been extensively used 
for cholera research in the past. This meant that there were several 
preexisting models for us to use in evaluating the role of CT and tolerated 
doses of the toxin were already established. We primarily used animals for ex 
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vivo work in determining the binding specificity of CTB under various 
conditions. We also used mice for in vivo toxin challenge experiments both 
by oral gavage and the ligated loop model. The in vivo work is discussed in 
more detail below.  
A knockout (KO) strain of C57 black6/J mice, deficient in synthesis of GM1 
and other more complex gangliosides, was also used. This particular strain 
has a partial deletion of the gene coding for b-1-4GalNAc-transferase. This 
deletion results in a limitation in ganglioside synthesis to only GM3, GD3 and 
GT3. Effectively this strain is a powerful control for GM1-independent CT 
intoxication and binding assessment. On a side note, the "GM1-KO" mice 
were originally acquired for a different research project but serendipitously 
lead to the discovery of GM1-independent intoxication. It should be noted 
that although WT and heterozygous (+/-) mice have been shown to make 
identical levels of GM1 in neuronal tissues and leukocytes, we could not 
detect any GM1 in the WT or +/- mouse small intestine by HPLC. This raises 
the interesting possibility that regarding the expression of GM1 in the 
intestinal mucosa, WT and KO mice could be very similar if not identical.  
One can make a strong argument for using more strains of inbred and also 
outbred mice to validate the data collected from C57 black6/J mice. A more 
diverse set of inbred strains would likely eliminate any inherent bias in relation 
to CT response and receptor expression that the C57 black6/J stain might 
harbor. Such a bias would be impossible to foresee and could have a 
tremendous impact. Still there are good reasons for using only one strain as 
I have done. One is that the KO mice were generated in a C57 black6/J 
background. This means that if I were to include other strains, I would have 
to set up laborious and time consuming cross-breeding to transfer the KO 
gene to the other strains. This would in turn consume time and resources 
impacting other parts of the project such as collecting data from human 
primary tissue. From an ethical point this would also force me to use more 
animals and thereby increase the suffering generated for obtaining my data. 
The aim of the studies was not to intricately investigate the effect of CT in 
mice and therefore work related to human tissue got precedence.  
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IN VIVO CT CHALLENGE 
To efficiently test our hypotheses regarding GM1-independenct intoxication 
and the ability of our polymers to block the effect of CT we used two variants 
of in vivo CT challenge; ligated loops and oral gavage. Working with live 
animals is a valuable complement to human cells and primary tissue. The ability 
to accurately measure the ultimate response to CT, namely fluid secretion, 
could only be done using animals. For the ligated loop models a slight 
modification was done to the conventional method by using the proximal 
section of the small intestine as opposed to the commonly used distal section. 
This since we noticed a significantly higher response to CT in the proximal 
sections. The literature also supports this observation in several other animals 
and it is therefore unclear to me why the conventional way of performing CT 
challenge in ligated loops in the distal part was established 
(88,221,240,241,250). 
Oral gavage is performed by feeding mice CT in a pH-buffered solution.  After 
a few hours the mice are euthanized and the length and weight of the intestine 
is recorded to assess fluid accumulation. This is a very effective method, but 
it has some drawback as discussed below. The other method called ligated 
loops are in short created by surgically exposing the small intestine and 
carefully tying off sections that are injected with CT. After several hours 
under anesthesia the mice are euthanized and the length and weight of the 
loops are recorded. This is a difficult and time consuming operation but more 
exact than the oral gavage method. The exactness stems from the fact that all 
the net generated fluid will stay in the loop and can be accurately recorded. 
You also have the possibility to visually assess the fluid accumulation during 
the ongoing experiment to choose an appropriate time span to use. In the 
oral gavage method, the time becomes a greater issue since you have to 
terminate the experiment to weigh and measure the intestine. If you do this 
too early you miss all or part of the response and thereby assay resolution. 
Similarly, if the response has been ongoing for too long some fluid has already 
been discharged. Since the release of stool is sporadic and the volume 
released unclear, the certainty of the fluid measurement in the intestine 
becomes hard to determine. Both methods are viable options but must be 
used with the respective drawbacks in mind.  
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ELISA 
The relatively inexpensive and time efficient ELISA-method has been an 
invaluable tool for me in mapping the CTB binding to various types of glycans. 
Working in a group of immunologists it was impossible to overlook the 
ELISA-method as a tool for assessing CTB binding to receptor candidates. 
Strictly speaking most assays were not ELISAs since no antibodies were used 
but the principle was the same.  
The main principle in an ELISA is to display receptors as a solid phase so that 
a liquid phase of ligands can bind and in turn be detected using reporter-
tagged antibodies. This is a good way of assessing an antibody response to a 
vaccine component or the level of a second messenger after treating cells 
with a novel compound. For my experiments I have primarily used 
glycoproteins as the solid phase and then horseradish peroxidase (HRP) 
conjugated to CTB to assess the binding of CTB to various glycans in different 
modes of display. This reductionistic approach let me in detail study how 
individual glycans could interact with CTB in a way that in not possible on a 
cellular level. However, this also meant that I had to use a synthetic and high-
density display of the glycans. This is obviously not how the glycans are 
displayed on the cell surface and it cannot be excluded that CTB binding 
specificity depend part of the protein or lipid as well as the glycan. Therefore, 
how the glycan is attached to the carrier protein or lipid can play a major role 
for the binding. Given those circumstances the resulting data cannot be used 
to determine the relative affinity for the glycans in relation to each other. The 
only thing that can be assessed is if the glycan in question binds CTB. A 
negative results does not mean that CTB does not bind to the glycan when 
naturally displayed on a cell. The data obtained from ELISA is still invaluable 
as a clean enough system to prove binding to a specific glycan in a cost- and 
time-efficient way. Together with other methods this helps create a better 
picture of binding specificity for CTB. 
  
HUMAN TISSUE  
The main goal for the thesis was to further the knowledge about CT 
intoxication of humans. To this end it was paramount to use primary tissue 
from the human small intestine. With regards to assessing CT binding and 
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intoxication primary tissue must be considered the best available 
representation of reality, second only to CT-challenge of healthy volunteers. 
Experiments on humans come with considerable ethical and practical 
concerns and cannot be justified in this case. To justify such a trial a CT-
blocking candidate of substantial potential (as well as subjection to extensive 
safety testing) would be necessary. Another possibility would be if a huge 
benefit for cholera patients was likely to be gained by performing the 
challenge. At no point during my studies did we fulfill any of these criteria. To 
make the most out of the donated tissue we employed several different 
methods aimed at understanding CTB binding and the receptor dependence 
for CT intoxication. In most cases cells were isolated by enzymatically 
degrading the tissue to analyze CTB biding using flow cytometry. Other more 
complex methods are described and discussed below.  
 
USSING CHAMBER  
The idea behind an Ussing chamber is that ion transport over a mucosal 
surface will result in an electrical current. This also makes the method very 
well suited for assessing the effect of CT and to test the efficacy of CT 
inhibitors. The mucosa is mounted as a barrier between two chambers 
containing isotonic solution. By exposing the apical side to CT, the natural V. 
cholerae infection is mimicked and the resulting ion flux can be measured as a 
current over the mucosal membrane. The current was calculated from the 
cross-membrane voltage and epithelial resistance. The epithelial resistance, as 
opposed to the whole mucosal resistance was obtained by using the Ussing 
pulse method (251). In short, a set of electrical pulses charges up the epithelial 
cells effectively making them into capacitors. As the applied current is turned 
off the charge is gradually released. The voltage is measured to enable 
calculation of the resistance. Normally the Ussing chamber method measures 
resistance directly but this will include the non-specific resistance of the 
subepithelial tissue making the measurement less exact. The voltage together 
with the resistance was then used to calculate the short circuit current. The 
short circuit current is an indirect measurement of the ongoing ion flux over 
the tissue membrane. The main drawback with this method is that the cells 
starts to die within hours, so long term experiments are not possible. In fact, 
the response time of CT was usually 3-4 hours and the tissue often started 
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to deteriorate after 5-6 hours. The Ussing chamber was used in paper 1 to 
evaluate the ability of different lectins to block CT-induced ion secretion.  
The method is very dependent on tissue accessibility and viability. Therefore, 
data acquisition took a long time and offered little room for titrating CT or 
the lectin to optimal concentrations. After completing paper 1 we therefore 
started to investigate alternative methods.   
 
CT CHALLENGE OF ENTEROID CULTURES 
In paper III we used a variant of the Ussing chamber to overcome the viability 
restraints. To do this we established cultures of stem cells from human small 
intestine called enteroids. The enteroids were grown and expanded in a 
medium with Wnt3A inhibiting stem cell differentiation according to an 
established protocol. When enough cells had been generated Wnt3A was 
removed to enable the cells to differentiate into several types of mature types 
found in the intestine (246). This was confirmed by flow cytometry and 
fluorescence microscopy showing that several mature cell types were present 
after differentiation. The cells also showed the same CTB-binding pattern as 
the primary cells isolated from the corresponding fresh tissue. 
Instead of using primary mucosal tissue to separate two chambers, enteroids 
were grown on membrane-mesh well inserts to complete confluence. The 
cells were then differentiated and treated apically with CT while the trans-
membrane voltage and resistance were continuously recorded. This enabled 
us to calculate the short circuit current similar to a normal Ussing chamber 
experiment. However, a normal Ussing chamber apparatus would directly 
measure the short circuit current. Therefore, our method is less exact and 
requires taking the cells in and out of the incubator several times during the 
experiment. The only benefit compared to the Ussing chamber is throughput. 
With this adapted method there is no limitation in number of samples as 
opposed to regular Ussing chamber setups that usually only accommodate 4-
8 samples at the same time. 
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RESULTS AND DISCUSSION 
This thesis is based on the work from 2 published papers and a manuscript in 
preparation. The papers are continuations of the work presented in another 
paper titled “Fucosylation and protein glycosylation create functional receptors for 
cholera toxin” (191). In the published paper I contributed with a minor part 
regarding data on CTB binding to primary cells from human colon. Although 
my contribution to the published paper appear minor, a lot of our own initial 
method development for the subsequent papers was done when acquiring the 
data. The paper did have a significant impact in the beginning of my studies 
but also contains a lot of data from experiments that I had no part in. I also 
did not contribute substantially to the intellectual process in writing the 
paper. For these reasons the paper was omitted from my thesis but is still 
significant enough to be acknowledged.  
The main findings from the study mentioned above was that fucosylated 
protein receptors seemed to play a significant role in CTB binding to various 
cells (191). Moreover, some of the toxic effect of CT could be related to 
fucosylated glycans. This gave us a good starting point for further investigation 
into the role of fucosylated glycans on CT intoxication in the human small 
intestine. Wands et al also identified the glycoproteins CD44 and CD66e as 
potential receptors for CT giving us a set of markers to investigate for 
correlation with CTB binding. 
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PAPER I - GM1 GANGLIOSIDE-INDEPENDENT 
INTOXICATION BY CHOLERA TOXIN 
This paper is the main paper of the thesis where several important findings 
were made. It has as strong link to the Wands et al 2015 paper and is in large 
a direct continuation of that work. Paper I mainly focused on characterizing 
the main CTB binding requirements of various cell types and also to shed 
some light on how CT binding and intoxication occurs in the human small 
intestine. We also wanted to evaluate CTB binding to cells with different 
ABO-blood groups to investigate if the above mentioned link between 
cholera severity and blood group O could be directly attributed to CTB 
binding. Finally, we also wanted to evaluate CT intoxication in a GM1-free cell 
line and a GM1-deficient mouse model as more human-like models of CT 
intoxication. 
 
CTB BINDING CORRELATES WITH LEWIS X EXPRESSION  
Whole human blood was stained with CTB to investigate binding to cells with 
different blood group antigens. The rationale for the experiment was to 
determine if the ABO-blood group of the donor had any effect on CTB 
binding to red blood cells. Surprisingly CTB binding was hardly detectable on 
red blood cells regardless of blood type. Instead granulocytes were shown to 
bind the most CTB by far of all blood cells (Fig 6A-B). This binding correlated 
with the Lewis X expression and was independent of the ABO-blood group 
of the donor (Fig 6A). Furthermore, the CTB binding could be blocked with 
L-fucose, the fucose-binding lectin AAL and the Lewis X glycan in both free 
form and attached to a protein (Fig 6C). This shows that CTB is able to 
interact with Lewis X or similar fucosylated structures on primary human 
cells. We could also show that CTB immunoprecipitated Lewis X-carrying 
proteins in a granulocyte cell line.  
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Figure 6. CTB binds to granulocytes independent of ABO-blood group. Whole human 
blood was stained with CTB and analyzed using flow cytometry. A) CTB binding to blood cell 
types with donors divided on ABO-blood group. B) CTB binding to blood cells compared to 
unspecific background, assessed using ovalbumin (OVA). C) CTB was preincubated with sugars 
or cells were preincubated with lectins before addition of CTB to granulocytes. Bars show % 
of unblocked CTB gMFI for the different treatments. D) CTB was preincubated with glycans 
or synthetic glycoproteins before addition of CTB to granulocytes. 
The GM1 glycan could also partially block CTB binding to granulocytes but 
the effect was saturated at about 50 % of CTB binding. By adding Lewis X at 
a non-saturated concentration together with a saturated concentration of 
GM1 we observed an increase in CTB block compared to GM1 alone (Fig 
6D). This strongly indicates the presence of two different binding sites since 
GM1 has a much higher affinity for CTB than Lewis X. GM1 could therefore 
not be outcompeted in the canonical GM1-site. This hypothesis was further 
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strengthened by data from ELISA experiments showing that Lewis X has no 
to little effect on CTB binding to GM1 and vice versa (Fig 7A).  
A more sensitive variant of ELISA using radiolabeled CTB showed that the 
CTB-Lewis X interaction was not present when Lewis X was attached to a 
lipid in the solid phase (Fig 7B). This suggests that CTB-Lewis X interactions 
are dependent on multimeric display of Lewis X and/or a protein back bone 
acting as a spacer for the attached glycan. It could also be that the protein 
backbone actively interacts with CTB together with the glycan. The latter is 
unlikely for tri-Lewis X HSA since there is 18 mole of tri-Lewis X for each 
mole of HSA, effectively occluding most of the HSA surface.  
 
Figure 7. CTB readily bind to protein- but not ceramide-linked Lewis X. A) Results 
from ELISA with HSA-linked Lewis X (left) and GM1(right) as solid phase, detected with CTB-
HRP with increasing concentrations of free Lewis X- or GM1-glycans. B) CTB binding to a solid 
phase of GM1 or Lewis X linked to ceramide. Detection was done by using inodine-125 labeled 
CTB. Relative binding was assessed from counts per minute (CPM). (C) Results from ELISA 
with varying concentrations of HSA-linked glycans as solid phase detected with CTB-HRP. 
Graph shows pooled data from three independent experiments. 
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CTB BINDS TO FUCOSE IN THE HUMAN SMALL INTESTINE 
The same pattern observed in blood was seen in cells freshly isolated from 
human small intestine. The epithelial cells bind CTB in a gradient from lowest 
on the villi to highest in the crypt. The CTB-binding also correlates with Lewis 
X and is completely fucose dependent (Fig 8A-B). We found that the GM1 
glycan could block binding to epithelial cells from some donors but had the 
opposite effect on others. This phenomenon was not seen for any of the 
other blockers such L-fucose or Lewis X (Fig 8B). We speculate that this 
could be due to patient variation of surface glycosylation or glycosylation of 
mucus. As for the granulocytes the binding could be blocked by the fucose-
binding lectin AAL and HSA-linked Lewis X and GM1, but not by the sialic 
acid-binding lectin MAL II or the galactose binding lectin PNA (Fig 8C-D). 
LacNAc, that is Lewis X without fucose (pre-Lewis X), did not show any 
interaction or blocking-capacity of CTB binding (Fig 7C and 8B).  
Unexpectedly we could not observe any correlation between CTB binding 
and the levels of CD44 or CD66e, although both were expressed on the 
isolated cells and indicated as potential CTB binders in Wands et al (191). 
This indicates that protein glycosylation might differ between cell lines and 
fresh tissue on the same proteins. Another possibility is that so many other 
types of receptors were present on the cells that no single glycoprotein could 
be singled out as correlative.  
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Figure 8. CTB binding in human small intestine is fucose dependent. A) Flow 
cytometry data of CTB and anti-Lewis X binding to EpCAM+ cells from a suspected secretor 
negative donor. B-D) Bar graphs of gMFI as % of CTB binding to small intestine epithelial cells 
after treatment with B) glycans, C) lectins and D) HSA-linked glycans. 100% represents CTB 
staining without any blocking and each dot represents a donor. Significance was calculated using 
a one-way-ANOVA with Tukey correction compared to CTB without block when not 
indicated otherwise (**** = p<0,0001, *** = p<0,005, ** = p<0,01 and * = p<0,05). 
GM1-INDEPENDENT INTOXICATION IN MICE AND CELL LINES 
To confirm the findings of CTB binding functionally, we first used a KO mouse 
strain lacking all complex gangliosides including GM1 and challenged them 
orally with CT. The KO mice had a stronger response to CT than WT 
littermates (Fig 9A). This shows that CT in vivo can intoxicate cells devoid of 
GM1. We could also show that the WT mice lacked detectable levels of GM1 
specifically in the small intestine, but that asialo-GM1 was present at a 
relatively high level (Fig 9B). Potentially asialo-GM1 acts as a decoy receptor 
for CT in wild type mice effectively protecting them from the more severe 
response seen in KO mice. Unexpectedly primary mouse epithelial cells 
almost exclusively depend on galactose for CTB-binding and AAL or Lewis X 
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has no to little blocking effect (Fig 9C). Furthermore, we could show that the 
GM1-negative rat cell line C6 was rendered more sensitive to CT when 
treated with the glycolipid synthesis inhibitor NB-DGJ. This was also true for 
the sialylation inhibitor 3Fax-Neu5Ac (Fig 9D). The increased sensitivity to 
CT after 3Fax-Neu5Ac is likely due to elevated levels of terminal galactose. 
Elevated levels of terminal galactose was confirmed by PNA stain (Fig 9E). 
This again shows that CT intoxication can occur in a GM1-independent way. 
 
Figure 9. GM1-independent intoxication both in vivo and in vitro. A) Graph on 
intestine-animal weight ratio for mice gavaged with PBS solution with or without CT. The data 
is pooled from several experiments and each dot represents one animal. One-way-ANOVA 
with Tukey correction was used to calculate significance (**** = p<0,0001, *** = p<0,005, ** 
= p<0,01 and * = p<0,05). B) Graph on the concentration of all GSLs in middle section in 
murine small intestine. C) Bar graphs on % of CTB binding to small intestine epithelial cells 
(WT black and KO gray) following pretreatment of the cells with lectins or CTB with glycans. 
100% represents CTB staining without blocking. D) C6 cells were exposed to CT for 1 h after 
which accumulated cAMP was measured. The signal is inversely correlated to cellular cAMP 
levels. E) C6 cells were stained with PNA and binding was assessed by flow cytometry. 
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CT INTOXICATION IS LIKELY DEPENDENT ON FUCOSE AND 
GALACTOSE IN THE HUMAN SMALL INTESTINE 
To test if the fucosylated CTB-binders could act as functional receptors in 
the human intestine, we utilized the fucose binding lectin AAL to block 
fucosylated glycans on fresh jejunal tissue. The response to CT was measured 
in an Ussing chamber showing that AAL could completely inhibit the ion 
secretion induced by CT. This was also true for the galactose-binding lectin 
PNA (Fig 10A). For this reason, it was hard for us to conclude if galactose 
and/or fucose were acting as functional receptors. It is possible that PNA and 
AAL can bind to the same glycan when both galactose and fucose are 
presented terminally on different branches.  
The argument can be made that fucosyl-GM1 could play an active role in CT 
intoxication, potentially acting as a ligand for both the canonical and the 
noncanonical, fucose-dependent, sites. However, to my knowledge the 
presence of fucosly-GM1 has not been shown in the small intestine of humans. 
In fact, only very low levels of regular GM1 can be detected (168). In a recent 
publication it was also shown by X-ray crystallography that fucosly-GM1 
interact primarily with the canonical site on CTB and not the fucose-binding 
one (252). 
 
Figure 10. Inhibition of CT intoxication by pretreating jejunal tissue with AAL and 
PNA. Human jejunal mucosae was pre-incubated with or without AAL or PNA before 
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mounting in  Ussing chamber and exposure to CT. A) Graph on percent difference of current 
in CT treated tissue compared to current of untreated tissue over time. Each dot represents 
a mean (4–7 donors tested in duplicates). Two-way-ANOVA with Tukey correction was used 
to calculated significance (compared to the CT only). * represent CT to CT + AAL comparison 
and † represent CT to CT + PNA comparison (**** = p<0.0001 and ** = p<0.01). (B) Graph 
on percent of start current for jejunal mucosae at 180 min. The tissue were exposed to 
forskolin (or forskolin analog NKH477) or bumetanide. Each dot represents a mean of 2–3 
donors tested in duplicates. C-D) ELISA with as solid phase of HSA-linked glycans, detected 
with biotinylated lectins and streptavidin-HRP C) or blocked with lectins and probed with CTB-
HRP D). 
By using a lectin that binds directly to cells we might also introduce a lectin-
dependent effect on the cells. It is possible that AAL and/or PNA have an 
effect opposite to that of CT and therefore falsely indicating an inhibition of 
CT intoxication. Controls using stimulatory chemicals were preformed and 
verified that the tissues were still viable and able to respond with the signal 
pathway induced by CT (Fig 10B). However, the controls cannot fully exclude 
the possibility of the abovementioned lectin effects. It can also be argued that 
PNA binds to GM1 and thereby inhibits CTB binding (Fig 10C). We therefore 
performed an ELISA with GM1-HSA as the solid phase. PNA as well as AAL 
was not able to inhibit CTB binding to GM1 (Fig 10D).  We therefore 
conclude that the lectins are not affecting the canonical CT-GM1 binding and 
intoxication pathway.  
 
CONCLUSION 
Paper I identifies that the majority of the CTB binding to primary intestinal 
epithelia cells is fucose-dependent and that fucose seems to be involved in the 
intoxication by CT. It also shows that GM1 and Lewis X binding occurred on 
at least two distinct sites on CTB. Moreover, we could show a GM1-
independent intoxication by CT both in vivo in mice and in a rat cell line. Taken 
together this proves an alternative intoxication route complementary to GM1 
in non-human mammals and the data suggests that this could also occur in 
humans. Finally, we present data indicating that fucose and non-GM1 galactose 
play a significant role in intoxication of human small intestinal tissue.  
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PAPER II - FUCOSYLATED MOLECULES 
COMPETITIVELY INTERFERE WITH CHOLERA 
TOXIN BINDING TO HOST CELLS 
Paper II focused on understanding the exact molecular properties and 3D-
display necessary for biding to the noncanonical site on CTB and was done in 
tight collaboration with Jennifer Kohler’s lab at University of Texas 
Southwestern. In addition, we were also interested in the effects that 
fucosylated and sialylated HBGA- and HMOs have on CTB-binding to various 
cell types. Therefore, a collaboration with Nicole Sampson’s lab at Stony 
Brook University, New York was also initiated. The Sampson synthesized 
polymer chains with fucose and glucose attached to them. This enabled us to 
evaluate if synthetic blockers could inhibit CTB-binding and thereby the 
possibility to use them for intoxication inhibition. This ties in to the second 
aim of this thesis evaluating the possibility of developing a novel type of CT-
blocking agent not based around the GM1 binding site.  
 
STERICAL DEPENDENCE OF HYDROXYL GROUPS FOR 
FUCOSE BINDING TO CTB 
L-fucose readily blocks CTB binding to both Colo205 and T84 cells and is the 
superior blocker compared to both the enantiomer D-fucose and a 
diastereomer 6-deoxy-D-glucose. This is in line with the findings in paper I 
where D-fucose was found to be a far inferior blocker of CTB-binding (253). 
This underlines the specificity of the noncanonical site on CTB even though 
it has far lower affinity than the canonical site.  
Using a structure-activity relationship approach for modifying the hydroxyl 
groups on L-fucose we could show that carbons 1, 4 and 6 are of great 
importance for CTB-binding. For the hydroxyl group on carbon 1 it is 
important to have it in an alpha-orientation for CTB binding. The hydroxyl 
group oxygen on carbon 4 seems to interact with CTB according to our data. 
Finally, we conclude that carbon 6 along with the hydroxyl group is also of 
importance for L-fucose-mediated blocking of CTB binding to cells (Fig 11A-
D). The other 3 carbons were less sensitive to modification and we could not 
detect any shift in blocking capacity for these other “fucose variants”. 
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Figure 11. Analysis of the importance of fucose hydroxyl groups for CTB binding. 
A) Schematic drawing of the L-fucose analogues used in this study. B-D) Inhibition of CTB 
binding to Colo205 cells assessed by flow cytometry. Analogues of L-fucose varying at carbon 
1 B), 2 and 4 C), and 5 and 6 D) (n = 3). Statistical significance was calculated using unpaired 
Welch’s test: *** p value < 0.001, ** p value < 0.01, and * p value < 0.05.  
HMOS BLOCK BINDING OF CTB TO COLONIC CELL LINES 
All above-mentioned experiments were made using mono-sugars but in the 
intestine CT would be interacting with complex glycans. As the next step we 
decided to use HMO-derived lactose with L-fucose or sialic acid additions. 
We choose to work with HMOs since they had been implicated in protection 
against diarrhea in breastfed infants (254,255). Lactose alone had a significant 
ability, albeit lower than L-fucose, to block CTB binding to Colo205, but less 
so to T84 cells (Fig 12A-C). The addition of L-fucose via an alpha1-2 linkage 
to the galactose in lactose (2´-FL) significantly increased the block of CTB 
binding compared to L-fucose alone. 2´-FL is present in high concentration in 
breast milk from secretor-mothers (2´-FL synthesis requires functional a 
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FUT2 gene) and is therefore not unlikely to affect CT intoxication in breast 
fed infants (196). However, this remains to be proven in functional studies. 
Surprisingly, the Lewis X-like 3´-FL (lactose with L-fucose in 1-3 linkage to 
glucose) did not show better blocking efficacy than L-fucose alone. When 
fucose was exchanged for sialic acid in alpha2-3 and 2-6 linkage on the lactose 
backbone all CTB blocking effect was mitigated (Fig 12A-C). This suggests 
that the sialic acid pocket in the canonical GM1-site was not important for 
blocking CTB binding to Colo205 or T84 cells. GM1 on the other hand could 
effectively block CTB binding to Colo205 cells but only partially to T84 cells 
indicating a major galactose-dependence for CTB-binding to Colo205 cells. 
 
Figure 12. HMOs can inhibit CTB binding to cell lines. A) Schematic drawing of the 
HMOs used. B) Inhibition of CTB binding to Colo205 cells assessed using flow cytometry and 
related to unblocked CTB binding. Statistical significance calculated using unpaired Welch’s 
test: **** p value < 0.0001 and * p value < 0.05. C) Inhibition of CTB binding to T84 cells was 
assessed using in-cell ELISA.  
LEWIS Y INHIBITS CTB-BINDING IN HUMAN SMALL INTESTINE 
To further investigate if more complex glycans would better inhibit CTB 
binding, we took a stepwise approach going from 2´-FL to the more complex 
A/BLewis-Y glycans. All intermediate glycans were tested for inhibitory 
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properties against CTB and a schematic drawing can be seen in figure 13A. 
We observed a dramatic improvement in inhibition efficacy for Lewis Y and 
this effect was not further improved but maintained in A- and BLewis Y (Fig 
13B). Further titration of Lewis Y and sialyl-Lewis X showed that both 
bifurcated glycans had a far better ability to block CTB binding than L-fucose 
and 2´FL (Fig 13C-D). This suggests that sialic acid is not always detrimental 
and might aid in glycan binding to CTB when oriented correctly. 
 
Figure 13. Lewis Y act as a strong inhibitor of CTB binding. A) Schematic drawing of 
the stepwise conversion of 2′-FL to A/BLeY. B) Inhibition of CTB binding to Colo205 cells 
assessed using flow cytometry. 100% is set to the fluorescence from CTB without blocking C) 
Graph on titration of several glycans that inhibit CTB binding to Colo205 cells assessed by flow 
cytometry. D) Graph on titration of several glycans that inhibit CTB binding to Colo205 cells 
assessed by in-cell ELISA. E) Inhibition of CTB binding to primary small intestine epithelial cells 
from humans assessed using flow cytometry. Different donors are represented by different 
symbols. Box plots encompassing low-high data points with the mean as an internal line. 
The same pattern was observed in primary epithelial cells from human small 
intestine. Lewis Y was superior to 2´-FL in blocking CTB-binding. Surprisingly 
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the LacNAc backbone of Lewis Y had no effect on CTB binding to primary 
cells whereas lactose had a significant effect on CTB binding to Colo205 (Fig 
13E). This indicates that the cell lines used were relatively similar to the 
primary tissue in human small intestine, but that galactose played a more 
dominant role in CTB binding to Colo205. Due to limited access to primary 
tissue we were not able to confirm all cell line findings on primary epithelial 
cells. 
 
FUCOSE POLYMERS EFFICIENTLY INHIBIT CTB-BINDING 
Finally, we tested if synthetic polymers with glucose and fucose could block 
CTB binding to both cell lines and primary small intestinal epithelial cells. The 
fucose-glucose polymer was found to be 150-200 times more effective at 
inhibiting CTB-binding than Lewis Y, while the glucose-only polymer had no 
significant effect (Fig 14A-C). However, a fairer comparison of CTB-blocking 
would be to normalize the fucose content of the polymer to that of Lewis Y. 
After normalization the polymer still had a 3-4 times better efficacy than Lewis 
Y showing that the polymeric display of fucose has a synergetic effect. This is 
most likely due to the fact that a long polymer can aggregate several CTB 
pentamers. Aggregation would be made possible both by the length of the 
polymer as well as by the 5 binding sites for fucose on each CTB pentamer. 
Several CTB pentamers can bind to the same polymer chain and also 
individually pentamers are able to bind more than one polymer effectively 
creating a lattice.  
 
Figure 14. Polymers with fucose block CTB binding to intestinal epithelial cells. A) 
Titration of polymers to assess blocking of CTB binding to Colo205 cells by flow cytometry. 
B) Titration of polymers to assess blocking of CTB binding to Colo205 cells by in-cell ELISA. 
Statistical significance was calculated using unpaired Welch’s test: *** p value < 0.001, ** p value 
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< 0.01 and * p value < 0.05. C) Assessment of CTB binding to primary small intestine epithelial 
cells from humans by flow cytometry. 100 % is set to gMFI of unblocked  CTB binding with 
unique symbols for each donor. Box plots encompassing low-high data points with the mean 
as an internal line. 
 
CONCLUSION 
To summarize we show in paper II that the CTB-fucose interaction is 
dependent the hydroxyl groups at carbons 1, 4 and 6. This effectively means 
that L-fucose must be linked via an alpha-linkage to the rest of the glycan chain 
in a cellular setting to bind CTB. It also means that the hydroxyl groups of 
carbon 4 and 6 must be oriented in such a way that they can interact with 
CTB. Furthermore, Lewis Y is a very potent natural blocker of CTB binding, 
but the HMO 2´-FL can also inhibit CTB binding at physiologically relevant 
concentrations (low mM) (196). This means that free glycans in both breast 
milk and the intestine could act as potent blockers of CT binding and thereby 
intoxication. Finally, we show that long synthetic polymer chains with fucose 
attached are very effective at inhibiting CTB binding to both cell lines and 
primary cells. The polymers therefore show promise as potential therapeutics 
for alleviating CT induced diarrhea. 
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PAPER III - FUCOSE-GALACTOSE POLYMERS 
INHIBIT CHOLERA TOXIN BINDING TO 
FUCOSYLATED STRUCTURES AND 
GALACTOSE-DEPENDENT INTOXICATION OF 
HUMAN ENTEROIDS 
This paper has a strong focus on evaluating the blocking capacity of 
glycosylated polymers, relating primarily to the second aim of the thesis. The 
polymers in paper III were a further development of the polymers used in 
paper II. These polymers has covalently attached fucose, galactose or a mix 
thereof to fully encapsulate binding to the canonical and noncanonical sites 
on CTB. Polymer blocking of CTB binding was evaluated using the same 
methods as for paper I and II, further building on the CTB binding 
requirements of cells from various tissues. The evaluation of functionally 
inhibiting CT by use of the polymers was done using human intestinal 
organoids. 
 
FUCOSYLATED POLYMERS EFFECTIVELY AGGREGATES 
CTB AND BLOCK LEWIS X BINDING 
After synthesis the polymers were tested for binding to CTB by dynamic light 
scattering and small angle X-ray scattering. The Gal50Fuc50 mixed sugar 
polymer clearly interacts with CTB having superior affinity compared to the 
fucose (Fuc100) or galactose (Gal100) polymers. The effect of Gal50Fuc50 
can be mimicked by mixing Fuc100 and Gal100 polymers (Fig 1, paper III). 
This suggests that by interacting with both the canonical GM1-site and the 
noncanonical HGBA-site the CTB interaction can be significantly stabilized. 
We provide evidence that the Gal50Fuc50 polymer forms aggregates with 
CTB, effectively crosslinking several CTB and polymer molecules. A 
schematic representation of this can be seen in figure 1C in paper III.  
Furthermore, evaluation of the polymer efficacy for blocking CTB binding was 
done using ELISA. HSA-linked tri-Lewis X or GM1 was used as the solid phase 
to act as ligands for CTB. The fucose-containing polymers could readily block 
CTB binding to tri-Lewis X in a dose-dependent manner. The Gal50Fuc50 
was by far the most potent blocker of CTB binding to tri-Lewis X but was 
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unable to block binding to GM1. The only polymer that could block CTB-
binding to GM1 was Gal100, although only partially. In fact, the other 
polymers increased the CTB binding to GM1 indicating formation of polymer-
CTB aggregates. We also investigated the effect of polymer length and 
concluded that the 100 sugar long polymers were far superior to the shorter 
ones in blocking of CTB-binding. This again supports the hypothesis of 
polymer aggregation of CTB and that this depends in part on the length of 
the polymer.  
Next, we made a CTB mutant (W88K) that lacks affinity for galactose and 
therefore also GM1 resulting in a valuable tool for studying GM1-idependent 
binding. Using ELISA, we could show that W88K has a maintained affinity for 
tri-Lewis X indicating that the mutation has no effect on the noncanonical site 
(Fig 2D-E, paper III). Some residual binding to of W88K to GM1 was detected, 
indicating that the sialic acid pocket could still accept its ligand. Therefore, 
when interpreting W88K binding data we cannot exclude the possibility that 
sialic acid accounts for some of the observed binding.  
To summarize, we show that the mixed sugar polymer Gal50Fuc50 is an 
effective inhibitor of CTB binding via the noncanonical site but is unable to 
block binding via the canonical GM1-site. We also provide further evidence 
that Gal50Fuc50 aggregates CTB. Finally, we show using W88K that CTB 
binding to galactose-pocket is independent of binding to the noncanonical 
HBGA-site. 
 
GAL50FUC50 BLOCKS CTB BINDING AND CT-INDUCED FLUID 
ACCUMULATION IN MOUSE SMALL INTESTINE 
To test the blocking efficacy of the polymers on live cells, we isolated various 
cell types from mouse tissues. CTB binding to B and T cells could be blocked 
by Gal100 and Gal50Fuc50 but not Fuc100 (Fig 3, paper III). When blocked 
with Fuc100 CTB binding to T cells increased, indicating binding to a strong 
CTB-ligand like GM1 that can maintain binding to heavy CTB-polymer 
aggregates. The lymphocyte blocking-pattern was largely repeated in epithelial 
cells from mouse small intestine, with the exception that Fuc100 had a weak 
blocking effect at low micromolar concentrations, compared to low 
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nanomolar concentrations for the other polymers (Fig 4, paper III). These 
results together indicate that the majority of CTB binding is not mediated via 
GM1, since Gal50Fuc50 could readily block binding. This conclusion is based 
on the fact that Gal50Fuc50 was unable to block CTB binding to GM1 in 
ELISA. The solid phase of GM1-coating in ELISA is of course not the same as 
the GM1-distrubution on the membrane of a living cell. However, I would still 
argue that the ELISA-data is representative of the cellular context since the 
affinity of CTB for GM1 is higher than that of the individual galactose-CTB 
interaction achieved on the polymer. Therefore, GM1 can easily, given time, 
outcompete the Gal50Fuc50 polymer one binding site at the time and thereby 
loosening up the aggregating effect.  
The promising results from staining cells with polymer-blocked CTB 
prompted us to perform CT inhibition experiments in vivo. Therefore, we 
used mice and injected ligated small intestinal ligated loops with CT pre-
incubated with Gal50Fuc50 and measured the fluid accumulation (Fig 4D-E, 
paper III). We observed a clear reduction in fluid accumulation with CT + 
Gal50Fuc50 compared to CT alone. However, CT + Gal50Fuc50 did not 
result in complete inhibition of fluid accumulation. This could indicate the 
presence of sialylated receptors, since the sialic acid pocket is left open by 
Gal50Fuc50. It could also be that other receptors are present in the small 
intestine that can compete with the polymer for CT binding. If so, it is highly 
unlikely that it is GM1 since we in paper I were unable to detect GM1 in the 
mouse small intestine by HPLC.  
To summarize, we confirm results from paper I that CTB binding to mouse 
cells is not dependent on fucose but rather on galactose. Furthermore, the 
data suggests that CTB binding is mainly mediated by non-GM1 glycans, 
although GM1 likely is contributing to CTB binding to lymphocytes. We also 
show that Gal50Fuc50 can partially inhibit CT induced fluid accumulation in 
mice. This indicates that Gal50Fu50 has a therapeutic potential in inhibiting 
CT intoxication.  
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CT INTOXICATION OF ENTEROID CULTURES IS ONLY 
PARTIALLY INHIBITED BY GAL50FUC50 
Taking into account that CT is an obligatory human disease and that CTB-
binding to mouse cells is fucose-independent, the findings in our mouse model 
required validation in a human model system. We first investigated how the 
polymers affected CTB binding to epithelial cells isolated from human small 
intestine. All polymers had a significant effect on CTB biding, although Gal100 
was inefficient and never completely blocked CTB-binding at the 
concentrations tested. Gal50Fuc50 was also far superior to Fuc100 indicating 
that the aggregation effect and/or the blocking of both sites have a significant 
effect on CTB binding. Considering the GM1-block results presented in paper 
I, that showed a large spread, it is likely that the ability of Gal50Fuc50 to block 
both sites has different impact on cells from different donors. We also 
observed that Gal50Fuc50 has a similar blocking effect on LTB binding 
suggesting that LT intoxication could potentially be ameliorated by this 
polymer.  
To test the polymer blocking of CT functionally we established long-term 
stabile enteroid cultures from some of the human donors. These cultures 
displayed various cell types present in the human small intestine (Fig 6A-D, 
paper III). They were therefore deemed a close representation of the freshly 
isolated in intestinal tissue. There are of course several issues with this 
assumption. This first and most obvious is that these cultures lack the 
connective tissue and undelaying immune cells as well as a luminal 
microbiome. It is known that the proteome and glycome of epithelial cells are 
affected by both immune cells and the intestinal flora (174,179). The enteroid 
cultures are therefore likely to suffer from several minor differences 
compared to the live tissue, which could impact CTB binding. Another 
possible source of discrepancy is the culturing itself. What cells are selected 
for/against, and if as a consequence subtypes of cell are lost, is impossible to 
control for at this point in time. The culturing conditions with high glucose 
levels are also likely to alter the proteome and glycome (242-244).  
Given such concerns we stained the cultured cell in the same way as the fresh 
tissue. However, the results confirmed that the cultured enteroid cells 
behaved similarly to the freshly isolated epithelial cells with regards to CTB 
binding and polymer block thereof. This indicated that no major discrepancy 
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was introduced during culturing that affected CTB-binding (fig 6E-F, paper III). 
Aside from polymer data, we showed that the CTB binding was primarily 
fucose-dependent since the mutant W88K bound equally well as CTB (Fig 6 
G-H, paper III). All this indicated that the enteroids could be readily used as 
a good representation of the epithelial tissue from the human small intestine.  
We therefore continued with functional testing of polymer blocking of CT 
induced intoxication. Enteroid cells were grown on permeable membranes 
that, when confluent, effectively separated the apical and basal fluids. This 
enabled measurement of trans-epithelial resistance and voltage (Fig 7A, paper 
III). From that we calculated the current representing the CT-induced ion 
flow. This was a quite complicated procedure and we have so far only been 
able to reproduce reliable CT-intoxication on cells from one donor. The 
preliminary results from this donor show that Gal50Fuc50 can partially inhibit 
CT intoxication (Fig 7B, paper III). In contrast, GM1 glycan completely 
blocked all CT intoxication showing that binding does not correlate with 
intoxication in humans. This is in line with the data obtained from ligated loops 
in mice, indicating that although the overall CTB binding patterns are different 
the functional receptor/s in both models depend on galactose.  
To summarize we have functional data from one donor strongly indicating 
that only a minority of the CTB binding to cells is actively taken up in a way 
that enables intoxication. This intoxication appears solely galactose-
dependent, as opposed to what the CTB-binding data suggested with 
fucosylated glycans as the major binders. This hypothesis is further 
strengthened by the fact that CTB binding to enteroids is only minimally 
inhibited by GM1 glycan and the galactose-binding deficient mutant W88K 
binds as well as wildtype CTB (Fig 6E and G, paper III). 
 
CONCLUSION 
In paper III we investigated and evaluated polymers based around the two 
main sugars described for CTB binding; galactose and fucose. We show that 
the mixed polymer Gal50Fuc50 is able to aggregate CTB pentamers and 
thereby block binding and partially block intoxication in mice and human cells. 
The results also confirm previous findings that CTB binding to murine cells is 
exclusively galactose dependent and that fucose is the main binder in the 
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human small intestine. Counterintuitively, we show that the fucose-
dependence for CTB binding observed in human tissues is not reflected in CT 
intoxication. In cells from one donor CT intoxication is, as in mice, occurs 
exclusively in a galactose-dependent way, indicating the fucosylated receptors 
acts as decoys rather than functional receptors. To obtain a better and clearer 
picture of human intoxication enteroids from more donors should be tested. 
As seen in paper I the blocking with GM1 glycan had a variable impact on CTB 
binding possibly representing a high variability in CT-receptors among 
humans.  
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THESIS CONCLUSION 
Summarizing the work of this thesis brings back memories of my first fumbling 
steps of realizing that glycans actually matter in biological systems, apart from 
being carriers of energy. Five years later I must constantly fight the urge to 
ask any college if he or she has considered that glycosylation could play a 
crucial role in their work. Although glycosylation is often ignored in most 
fields of life science, it is no excuse for me to narrow my perspective this way. 
My exaggerated glyco-focus is one of the biggest biases I have noticed in 
myself. Another related bias of mine is the importance of fucose for CT 
intoxication (with some galactose contribution), with complete disregard for 
sialic acid. The third bias consists of an obsession with the idea that CTB binds 
to HBGAs and fucosylated HMOs, leading me to ignore other investigation 
into other glycans that might bind CTB. 
For the reasons stated above the data in papers I-III lack thorough 
investigation of the role of sialic acid for CT intoxication. The few 
experiments done indicate that it has only a small, if any, role in CT 
intoxication. However, as shown in paper III binding of CTB does not always 
correlate with CT intoxication, e.g. I had no rational reason for excluding 
investigation of known CTB binders. Only in hindsight have I realized this 
error. 
I also have to admit that the aims were only partially answered during my 
studies. For the first aim regarding the role of fucosylated glycans in CT 
intoxication the results from paper I and III were somewhat contradictive and 
no conclusion regarding whether the fucosylated receptors indeed facilitates 
or act as decoys could be drawn.  For the same reason the second aim, 
investigating if synthetic polymers can block CT intoxication, was also left 
partially unanswered. The functional data was somewhat ambiguous showing 
that the GM1 glycan could completely block intoxication whereas the 
Gal50Fuc50 had a partial effect.  
However, I could firmly conclude that CTB binding to human small intestinal 
epithelium is mainly mediated via the noncanonical site dependent on fucose 
for binding. I therefore speculate that CTB binding to these cells is mainly 
mediated via HBGAs such as Lewis X, Y, A/B-Lewis Y and blood group ABO-
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antigens. Given that these antigens readily bind CTB and are known to be 
expressed by epithelial cells this is not an unfair assumption. In a subset of 
human donors (suspected to be secretor negative) we could also show that 
an antibody against Lewis X directly inhibited CTB binding (Fig S5E, paper 1).  
Given our somewhat inconclusive data there are several possible roles for 
fucosylated receptors in CT intoxication. It can be argued that fucosylated 
receptors act to facilitate binding to GM1 by helping to “fish out” CT from 
3D-solution in the intestinal lumen to the near-2D surface of the epithelial 
cells. This could potentially help facilitate CT intoxication by increasing the 
chance of CT-GM1 encounters. This hypothesis cannot be excluded given the 
available data, but neither can a decoy-hypothesis be excluded where 
fucosylated receptors actively counteract CT intoxication by preventing 
functional uptake. 
I argue that the two alternatives above are less likely for CT mediated 
intoxication in the human small intestine. If fucosylated receptors facilitated 
intoxication in a significant way, one should expect the Fuc100 polymer to 
have an impact on intoxication by effectively eliminating the fucosylated 
helper-receptors. The opposite would be true if fucosylated receptors were 
decoys, as Fuc100 would eliminate this protective mechanism and thereby 
further sensitizing the cells to CT.  
As we were unable to observe any of these proposed outcomes, I propose a 
third alternative. I believe that fucosylated receptors are largely inactive 
bystanders with limited impact on CT toxicity. It has also been shown, albeit 
in murine thymocytes, that as few as 10 CT molecules can elicit a significant 
cellular response (256). This indicates that only a small amount of CT has to 
enter a cell to elicit a response, most likely rendering weak affinity decoys 
ineffective against CT. With all this said I must again stress that I cannot prove 
my conviction using the experimental data at hand. Instead this subject needs 
further investigation to fully elucidate the role of fucosylated receptors in the 
human small intestine.  
Furthermore, we show that galactosylated non-GM1-repetors can act as 
functional receptors for CT. This was proven in KO mice lacking the ability 
to synthesize GM1 since they were even more sensitive that WT mice. To 
add the WT mice did not have detectable levels of GM1 indicating that also 
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WT intoxication was due to non-GM1, yet galactosylated, receptors. A strong 
galactose-dependent intoxication was also observed in the GM1-free rat cell 
line C6. In C6 cells sialic acid had a detrimental effect on intoxication, whereas 
fucosylated receptors seemed to contribute to intoxication, albeit to a minor 
degree. Finally, a non-GM1 intoxication was indicated by the effectiveness of 
the two lectins AAL and PNA in inhibiting CT induced ion secretion in 
primary human tissue. AAL, binding fucose, and PNA, binding galactose were 
unable to inhibit CTB binding to GM1 in ELISA, leading me to conclude that 
CT-intoxication in human small intestine is likely not dependent on GM1. 
However, it can be argued that the lectins themselves might skew the data by 
eliciting their own effects. Therefore, functional data from more human 
donors is called for using various blocking methods.  
To my knowledge, the level of GM1 on human small intestinal epithelial cells 
has only been measured on tissue from one donor. I therefore call for a more 
comprehensive study involving more donors to be able to conclude the level 
of GM1 and thereby the likelihood of it acting as a receptor of CT. To me it 
seems paramount that showing physiologically relevant levels of a candidate 
receptor in the target tissue must precede the development of a receptor 
dogma. For CT this procedure has clearly not been observed and results from 
animal studies have been extrapolated onto humans without sufficient 
evidence.  
  66 
FUTURE PERSPECTIVES 
As scientists we are supposed to be seekers of truth and knowledge. It is at 
the very core of our profession. Often, I find that my thoughts still linger at 
the challenges at work long after I come home. This obviously leaves me less 
attentive, and therefore also a lesser husband and father. A significant cost to 
pay not just for me, but possibly therefore also a cost that is worthy of the 
task. Revealing truths that in turn enable subsequent gathering of more 
knowledge and truths in a never ending loop. To enable this loop is paramount 
since no scientist alone can solve the complex biological problems we are 
facing. We need to build on each other’s work and step by step try to paint 
the full picture. 
Therefore, all data published must hold a high quality as well as truthfully 
representing the phenomenon studied. In life science today I see a need for 
better access to good and truthful models. A solid and reproducible model is 
not by default going to produce data truthful to the aspect it is set out to 
mimic. In each case a decision has to be made if the model is good enough 
and not simply “the best we have right now”. After over 8 years in life science 
I suspect that far too often the truthful answer to that question is “no”. No, 
the model is not good enough, but it is the best we have right now. So, we 
use it regardless out of laziness and convenience. 
We are supposed to be seekers of truth. It cannot be enough to use only one 
or two model systems with a “ it’s the best we have right now”. A scientist 
should know that the devil is in the details. So why accept findings in a so-
and-so model as truth? False data, although unintentional, has unlimited 
capacity to do damage in leading others endeavors astray. Old habits die hard, 
and so does published false data. Our standard must be held higher than that! 
How can we otherwise motivate spending huge amounts of tax money and 
private funds, if nothing real comes out of our work?  
A good step in the direction of creating “good enough”-models I propose that 
a large biobank is set up with access to enteroids from a diverse set of donors. 
This would be very expensive but at the same time also a valuable resource 
in enabling truthful research. The biobank would represent at least part of the 
genetic diversity seen in humans and thereby be better suited than the inbred 
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mouse models or cell lines often used. By enabling a broad access to this 
biobank and training the scientists on how to handle the delicate enteroids, 
more groups could expand their model repertoire and validate findings form 
other cheaper and easier models. The enteroid cultures can also be expanded 
to encompass more cell types effectively including other fields such as 
immunology and neurobiology.  
More verification of findings done in animal models and cell lines by usage of 
human-like models is in my mind a good and necessary way forward. This 
would be a small step, but in general I believe that this more systematic and 
large-scale approach is called for. By having access to large and diverse sets 
of human-like models scientist can systematically truly verify initial findings in 
simpler and cheaper systems without exposing humans to unnecessary risk. 
This verification would obviously be expensive and time consuming, giving 
that only larger research groups with sufficient manpower and founding could 
undertake this. Although unfair to smaller groups and possibly suffocating 
some of the current creativity, a consolidation would give the huge benefit of 
quickly reaching a well-founded conclusion for a given question. In my limited 
experience I find that the amount of creativity is not an issue for us scientists. 
Instead I have often found that the limiting factor is the physical means to 
truthfully verify or disprove a hypothesis.  
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